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ABSTRACT
Cancer is a disease associated with uncontrolled cell proliferation or reduced cell death, either
of which can lead to tumorigenesis. A possible route through which cancer can develop is by
breakdowns in the signaling cascade of proteins at the cellular level. Since there are many ways
in which such breakdowns can occur, anti-cancer chemotherapeutic drugs show varying degrees
of efficacy in different patients. Thus, there is an urgent need to personalize the drug treatment
regimen for better response to treatment while trying to reduce the side effects of these drugs. One
way to meet this need would be to try every possible drug combination on cell lines extracted from
a patient and find the combination with the least number of drugs in the mix but providing the best
possible output. Although this method may work it is tedious and time consuming as the number
of combinations increase exponentially with every new drug that is introduced into the repertoire.
First, we consider the problem where the tumor is homogeneous in nature but the mutations
within the mutated cells are unknown. We use Boolean network models with monotonicity prop-
erties to reduce the number of test cases, while still getting the best possible combination with the
least number of drugs in the mix. This approach is efficient both in terms of time required and the
costs involved. This method has also been applied to both simulated and real-world data collected
from fibroplasts using qPCR to demonstrate the usefulness of the method.
Another important area of study in cancer research concerns the heterogeneous nature of tu-
mors. The clonal evolution of tumors is the driving force leading to heterogeneity in cancer tissues.
Thus, in order to customize the treatment of cancer we need to be able to better model the hetero-
geneous subpopulations in the tumor. This can be done by estimating the impact of the various
sub-populations and by modeling the interplay of various sub-populations within the heteroge-
neous tumor. Prior works in the literature have already addressed the problems of estimating the
proportion of the sub-populations within a tumor and of modeling the interaction between the var-
ious sub-populations. In this work we present a way to improve the accuracy of the Bayesian
ii
hierarchical model which helps in estimating the proportional breakup of the tumor population.
Additionally, it looks at ways to use the knowledge of the proportional breakup of tumor sub-
populations and the interplay between the various subpopulations to help customize the treatment
for the patient by making use of evolutionary game theory. We demonstrate the improvement of
the presented methods as compared to the existing Bayesian hierarchical model by applying these
techniques to qPCR and fluorescent data.
Finally, the problem becomes more challenging when the nature and the number of the sub-
populations are variable and difficult to estimate. In this work, we present a feasible way to find
the best possible drug combination for such a scenario by training two neural network models on
synthetic and real-world cancer data. Then we test each model, to verify their effectiveness and to
demonstrate their usefulness in choosing the appropriate combination therapy. The models were
evaluated on synthetic qPCR data and fluorescent data obtained from experiments.
The results obtained from these methods take us a step closer to the realization of customized
treatment for cancer patients. This will not only make the treatment more effective but also help
reduce the side effects of the drug treatment.
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In multi-cellular organisms different cells work in harmony to sustain life. Each cell serves a
specific purpose in the organism after which, in most cases, it dies via the process of programmed
cell death. The coordination between different types of cells in an organism is brought about by
various types of extrinsic and intrinsic signaling in the cells. Extrinsic signaling or communication
between cells can be mechanical, electrical or biochemical in nature. Mechanical signaling is due
to forces exerted on the cell or produced by the cell which in turn can be sensed and responded to by
the other cells. Electrical signaling is usually carried out by nerve cells via transmission of action
potentials whereas biochemical signaling involves various biomolecules such as proteins, lipids,
ions and gases. Proteins for example, by virtue of their amino acid sequence and spatial conforma-
tion, transmit highly specific signals to the desired target. Generally, the somatic cells in our body
depend on proteins for signaling. The chain of sequential biochemical protein interactions within
the cell, usually triggered by an extrinsic signal received by the cell receptor, forms what is known
as a signaling pathway. A breakdown in signaling can lead to various diseases. Such breakdowns
can occur due to mutations in the exon region of the genes, chromosomal rearrangements within
the DNA sequence or due to viral infections. These breakdowns can in turn lead to the production
of faulty proteins which can inhibit proper signal transduction. Not all breakdown in signaling
would manifest itself as a change in the phenotypic behavior of the cell, due to the inherent redun-
dancy present in the cell’s signaling mechanism such as feedbacks, alternate signaling pathways,
etc.. However, when these breakdowns cause the cell to divide rapidly and/or inhibit the apoptosis
of cells, it leads to growth of tumor. Thus, in cancer patients, the tumor cells tend to have a faulty
signaling which causes them to rapidly divide and/or not follow the path of programmed cell death
known as apoptosis [1, 2]. Hence this leads to cancer cells using up the resources, earmarked for
other cells, to grow in a limitless fashion, ultimately leading to the death of the organism. There
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are various anti-cancer drugs which target different proteins along the signaling pathway but as the
nature of cancer varies from one person to another the same drug combination may perform well
for a particular patient and not at all in the case of another. Thus, there is a critical need to tailor
the drug treatment regimen to the individual patient, leading to what is commonly referred to as
personalized therapy. The goal in this work has been to identify the best possible drug combination
which helps to control the growth rate of the tumor in general and with reduced side effects. To
achieve reduced side effects, we simply try and find the smallest subset of drugs which is most
efficient in slowing down tumor growth. We primarily focus on cancer caused by mutations on
well-known signaling pathways in this work, but the specific nature of the problem dealt with are
described in greater detail [3, 4, 5] in the sections 2, 3 and 4. In subsection 1.2 we look at the
organization of this work.
1.2 Organization
In order to help customize the treatment for cancer patients we start by breaking up the problem
into various subproblems. Thus, we consider the four different scenarios with respect to the nature
of mutations within the tumor cells. First, we consider the scenario where the tumor consists of
a homogeneous subpopulation of cancer cells and the nature of mutations are known. In such
a case the problem of identifying the drugs for treatment becomes trivial as we simply use the
drug combination that gives us the best results by making use of signaling pathway knowledge.
Thus, we do not invest our efforts on this problem but rather focus on solving the remaining three
scenarios.
Second, we consider the scenario where the tumor is homogeneous in nature [3] but the nature
of the mutations is unknown. This is dealt with in section 2. In this case we look at signaling path-
ways of a particular type. The pathways dealt with should satisfy the condition of monotonicity.
To solve this problem, we make use of the properties of monotonic Boolean networks which are
described in the next section.
Third, we consider the subproblem where the tumor is heterogeneous in nature [4] but the
nature of the various subpopulations is known. In this case we look at the observation data and
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estimate the relative proportion of the various subpopulations that are present within the cell. We
make use of a Bayesian hierarchical model to achieve this. Once we have the relative ratios of the
different subpopulations we identify the target subpopulation for drug therapy by making use of
evolutionary game theory. The problem is described and dealt with in section 3.
Fourth, in section 4 we look at the situation where the total number of subpopulations within
the heterogeneous tumor is unknown and/or the nature of the mutations in some or all of the
subpopulations is unknown [5]. This is dealt with by making use of feedforward neural networks
which are trained on previously known patient data.
Finally, in the section 5 we conclude this work by summarizing our work and looking at pos-
sible avenues for future research so as to bring the dream of customizing cancer treatment for
patients closer to reality.
3
2. BOOLEAN NETWORKS WITH MONOTONIC PROPERTIES AND THEIR
UTILIZATION IN THE EFFICIENT SELECTION OF KINASE-INHIBITOR
COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
2.1 Introduction
Designing proper drug treatment for cancer requires the understanding of the overall multivari-
ate nature of protein-protein interactions instead of focusing on their simple pair wise interactions.
The extreme complexity of studying multivariate protein-protein interactions has historically mo-
tivated biologists to look only at the marginal relationships between interacting proteins. Thus,
to develop a proper understanding of cellular behavior, we need to develop multivariate models
consistent with known prior marginal relationships between interacting proteins. There are various
techniques in the literature [6] which are used to model the signaling behavior of cells. Differential
equations based on the law of mass action [6, 7, 8], for example, provides a general framework to
model signaling pathways. By making certain assumptions one can model the cellular signaling
by a system of non-linear ordinary differential equations (ODEs) in variables representing protein
and mRNA concentrations. However, for a signaling pathway, which involves a large number of
proteins, to write down such equations using the mass action models we need to be able to predict
the rate constants for the various biochemical reactions which occur in the pathway. This requires
us to obtain a lot of time course data for the various proteins in the pathway. Also, as we are
dealing with mutated pathways in cancer cells some portion of the pathway may behave unexpect-
edly due to mutations and thus the system would not be deterministic as is normally assumed for
such models. To deal with this we can make use of probabilistic methods which makes use of the
Langevin approach [6] which also adds a noise term to the differential equations to account for the
non-deterministic nature of the pathways. We can also make use of the Fokker-Planck approach
[6, 9] which involves equations describing the changes in the probabilistic distribution of protein
states (i.e. concentration of proteins) as a function of time. These PDEs are extremely difficult to
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solve as compared to ODEs [6]. Also, as these are probabilistic models, lots of data points would
be needed so as to reduce the error in prediction.
Before choosing the model, we need to ask ourselves a few questions such as whether we are
interested in the time course behavior of the pathway or whether we are interested in the equilib-
rium state of the pathway. In our case we are concerned with the equilibrium state of the outputs
when drugs are applied. Another goal in our case is to predict the behavior of pathway with a
minimal number of data points so that the process is time efficient and cost efficient. These re-
quirements rule out the use of statistical or differential models for modeling the signaling pathway.
What we need to predict is if a reporter protein for the signaling pathway is up regulated or down
regulated and thus there are two possible states for a protein/gene. This is nicely represented by a
discrete Boolean model. A method using such a Boolean model was presented in [10]. That paper
used digital logic to understand the mechanics of a signaling pathway and to map that information
into a Boolean network. Various other works on cellular signaling also have used Boolean net-
works [11, 12, 13, 14] to model the protein signaling within the cells. The reason behind using
Boolean network models is that many proteins/genes inside the cell exhibit an ON/OFF switch
like behavior [15] which can be easily modeled using the binary states 0 and 1. Subsequently,
in [16] such a network was used to categorize mutations in genes/proteins of the corresponding
pathway and predict the effect of different kinase-inhibitor combination therapies administered to
the patient. The work in [16] considered only the single mutation case but in most cancers, the
signaling pathway could have multiple mutations. This motivates the topic of this section, which is
to try and develop a method to efficiently arrive at effective combination therapies when there are
multiple mutations in the signaling pathway. The main objective of the section is to help reduce
the labor associated with testing the effect of drug combinations on tumor tissue, in the process of
identifying the best drug combination for the patient. Thus, our primary emphasis is on reducing
the number of drug combinations which needs to be manually tested before the best drug combi-
nation can be identified. The approach makes use of certain monotonicity properties that can be
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associated with Boolean networks used to model signaling pathways. 1 In this section we focus
on the well-known MAPK signaling pathway and the mutations of the proteins/genes associated
with it. We do not consider the behavior of the MAPK signaling pathway in the presence of viral
infections or in the case of chromosomal rearrangement.
In the following subsections we start off by first investigating the monotonic properties of
fixed Boolean networks. Then, we show how these properties can be utilized to make an efficient
selection of customized combination therapy. This is followed by the presentation of an algorithm
to infer the best possible drug combination. To bring out the usefulness of our method, it has been
applied to synthetic data generated from the prior knowledge of MAPK network. The method has
also been applied to experimental data collected by applying some of the drug combinations on
normal adult fibroplast cell lines. To test the success of our method we simply see if our method is
able to identify the best possible drug combination with least number of drugs as mentioned earlier,
which it does. We then discuss the results and talk about the possibilities for the improvement of
the algorithm in the future followed by a concluding statement.
2.2 Fixed monotonic Boolean networks
To arrive at Boolean networks with monotonicity properties, we first represent signaling path-
ways as digital networks following the approach introduced in [16]. Here, a protein which is active
is represented as having state 1 while one which is inactive is represented as having a state 0. Mu-
tations can either cause a protein to become constitutively active or render a protein inactive. Such
anomalies can be represented as stuck-at-faults [17] when the pathway is mapped into a Boolean
network. Signaling breakdowns which introduce new signaling mechanisms to existing pathways
can be represented as bridging faults [17] in the corresponding Boolean network. In this section,
we will consider only signaling pathways without any feedback and the only faults considered will
be of the stuck-at fault type. Furthermore, we will assume that only one particular combination of
mutations has occurred in the cells making up the cancerous tissue; in other words, the cancerous
1Note that in the MAPK signaling diagram shown in this section, there are various proteins such as PTEN, AKT,
mTOR etc. which are not explicitly part of MAPK pathway but have been shown. This is because they are known to
interact with the MAPK pathway.
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tissue is homogeneous.
These assumptions serve as a starting point for dealing with the issue of identifying the best
possible drug combination for a patient. Now, in terms of digital logic, we can think of cancer as
being caused by a combination of various faults in the signaling pathway. In reality a signaling
pathway can have more than one cancer causing stuck-at-fault or bridging faults with various sub-
populations of cells harboring different combinations of mutations. Thus, in reality, a cancerous
tissue will be composed of a heterogeneous population of cancer cells. However, as mentioned
earlier, we will consider the case where there is only one kind of sub-population of cancer cells with
multiple stuck-at-faults. Our aim is to arrive at a combination of cancer drugs from an existing list
of protein kinase inhibitors, which are known to target the signaling pathway at various locations,
such that any particular patient’s cancer can be treated optimally both in terms of reduced side
effects [18, 19] and maximal suppression of the effect of disruptive mutations. In other words,
our goal is to find a drug combination with the best possible output and the least number of drugs.
For illustrative purposes, we will be considering the Mitogen-activated protein kinase (MAPK)
signaling pathway. The MAPK pathway has been considered here as a mutation along that pathway
is normally a necessary step in the development of tumors [20, 21].
Before plunging full swing into the solution of the problem we first take an intuitive look at it
from the point of view of signaling pathway knowledge. We know certain mutations, for example
Ras mutation in MAPK [22], are associated with cancer. In terms of digital logic this means that a
stuck-at-one fault at a point in the MAPK digital diagram corresponding to Ras will always try to
promote cancer which means activating downstream proteins and transcription factors regardless
of whether the upstream proteins are activated or not. A protein kinase inhibitor at a proper target
on the other hand would always try to suppress the cancer by preventing downstream proteins and
transcription factors from being activated by the mutated protein.
Looking at this from a digital standpoint, we see that if we drive Ras from state 0 to state 1 (i.e.
mutation) it would cause downstream transcription factors such as SP1 to be driven from 0 to 1 or
stay at the same state but never allow them to go from state 1 to state 0. Similarly applying a drug
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such as U0126 which targets location MEK1 will drive MEK1 from state 1 to state 0 which in turn
will always cause SP1 to go from state 1 (active) to state 0 (inactive) or stay unchanged but never
allow it to go from state 0 to state 1. Based on this line of reasoning, we see that there is a kind
of monotonic relationship between fixed upstream and downstream proteins/transcription factors
regardless of the activation status of other proteins. This motivates us to take a deeper look into the
structure of Boolean networks, which we do next.
When representing a signaling pathway as a Boolean network, all the interactions in the path-
way will be represented using only primary gates, universal gates and buffers. We now proceed to
study the properties of networks constructed out of these modules.
2.2.1 Properties of fixed monotonic Boolean networks
The concept of monotonicity in Boolean circuits has been utilized in the context of different
topics [23, 24] such as reliability theory, theory of complexity and computation models, cancer
diagnosis [25], etc.. Authors working on different topics tend to use a variety of ways to define
monotonicity [24] to suit their needs. Thus, to enhance the clarity of presentation, in the context of
cellular signaling, we begin by introducing some terminology and notation of our own. Let ℵ be
a Boolean network. Define the network class ℵζ to be made up of all possible networks that can
be obtained by introducing stuck-at-faults at various locations in network ℵ, with the no-fault case
included in the class. Note that stuck-at zero and stuck-at-one faults lead to different networks in
the network class ℵζ . We see that ℵ ϵℵζ and we call it the primary network of class ℵζ as it has no
variables with fixed values unlike other networks of the same class which have at least one variable
forcibly held at a fixed value. For any variable V we represent a change of value of that variable
from 0 to 1 as 0 → 1 and from 1 to 0 as 1 → 0. So, if V goes from state 0 to 1 we write it as
V : 0 → 1. Similarly, we write V : 1 → 0 if the value of V goes from state 1 to 0. A network
scenario is simply defined as a network belonging to the network class ℵζ with fixed values (0 or
1) at the locations corresponding to the inputs of the primary network ℵ. Different combination
of input values for a given network in ℵζ lead to different network scenarios. For a network ℵi
belonging to ℵζ we say a location is a clean location if there are no stuck-at-faults in the location
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or else the location is a faulty location.
We consider logic variables X and Y with X upstream and Y downstream in the network ℵ.
If forcing X : 0 → 1 causes Y : 0 → 1 in at least one network scenario, while letting Y to stay
unchanged or go from 0 to 1 in other network scenarios, then we represent it by X ↑ Y . If the
same transition in X causes Y : 1 → 0 in at least one network scenario while letting Y remain
unchanged or go from 1 to 0 in other network scenarios, we represent it by X ↓ Y . If a change
in the value of X does not cause a change in the value of Y in any of the network scenarios, then
we represent it by X|Y which means Y is independent of changes in X . This is the case when Y
does not lie downstream of X. Note that when Y is downstream of X then it is also possible to have
X|Y depending on the structure of the network.
For a network ℵ and a pair of variables X and Y in the network which are upstream and
downstream respectively of each other, if there exists either a monotonic relationship X ↑ Y or
X ↓ Y , when Y is not independent of X , we call it a fixed monotonic relationship between X
and Y . If upstream variable X and downstream variable Y are related either as X ↑ Y or as
X|Y then we represent it by X ⇑ Y . Similarly, we define X ⇓ Y as when X and Y are related
either as X ↓ Y or as X|Y . Thus X ⇑ Y and X ⇓ Y can be thought of as weaker versions of
fixed monotonic relationship between X and Y where the requirement that for at least one network
scenario Y changes appropriately in response to X : 0 → 1 is relaxed.
If all upstream-downstream variable pairs (X,Y ) where Y is dependent on X share a fixed
monotonic relationship, then the network ℵ is called a fixed monotonic network. Note that in a
fixed monotonic network if upstream-downstream variable pairs (X, Y ) does not satisfy X ↑ Y
then X ⇓ Y . Similarly if (X,Y ) does not satisfy X ↓ Y then X ⇑ Y .
All throughout the section Σ will denote the logical ‘OR’ operation involving two or more
variables while Π will denote the logical ‘AND’ operation.
Property 1:
Statement: The primary gates (including buffer) and universal gates introduce fixed monotonic
relationships between input variables and the output variable as shown in Table 2.1.
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Table 2.1: Relationship between input and output for primary gates and universal gates.







Proof: Consider a primary gate such as ‘AND’ or ‘OR’. For one of the inputs X and the output
Y we see that Y = X.
∏
w ̸=X w or Y = X.
∑
w ̸=X w depending on whether it is an ‘AND’ or
‘OR’ respectively, where w represents inputs to the gate. For an ‘AND’ gate, if
∏
w ̸=X w = 1 then
for X : 0 → 1 we have Y : 0 → 1 and for
∏
w ̸=X w = 0 we have Y remains unaltered at state
0. Thus, we can say X ↑ Y when X is one of the inputs of the ‘AND’ gate and Y is the output.
Similarly for the ‘OR’ gate, if we have
∑
w ̸=X w = 0 then for X : 0 → 1 we have Y : 0 → 1
and for
∑
w ̸=X w = 1 we have Y remains unaltered at state 1. Thus, again we can say that X ↑ Y
when X is one of the inputs of the ‘OR’ gate and Y is the output. Now consider a ‘NOT’ gate or
a simple buffer. For a ‘NOT’ gate we can see that for X : 0 → 1 we have Y : 1 → 0. Hence
X ↓ Y when X is the input of a ‘NOT’ gate and Y is the output. In a buffer, for X : 0 → 1 we
have Y : 0 → 1. Therefore X ↑ Y when X is the input of a buffer and Y is the output. Using
an argument similar to that used for ‘AND’ and ‘OR’ we can see that for universal gates ‘NAND’
and ‘NOR’ we have X ↓ Y . Table 2.1 presents the relationship between input X and output Y for
various primary gates and the universal gates. Note that such a fixed monotonic relationship would
not hold if ‘XOR’ (exclusive or) was used instead of primary gates or the universal gates.
Definition: The gates for which X ↑ Y , given input X and output Y, will be referred to as the
positive gates. Similarly the gates for which X ↓ Y will be referred to as the negative gates.
Property 2:
Let there be three variables X , Y and Z in network ℵ such that X is upstream of Y and Y is
upstream of Z. Also, all the paths from X to Z pass through Y . Now we consider five possible
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cases.
Statement (a): If X ↑ Y and Y ↑ Z then X ⇑ Z.
Proof: If X : 0 → 1 then Y : 0 → 1 or Y is unaltered. When Y : 0 → 1 then Z : 0 → 1 or Z
is unaltered. If Y is unaltered then Z remains unaltered. Thus, we can see that either X ↑ Z or
X|Z. Note that X|Z can occur when no common network scenarios exist where X : 0 → 1 leads
to Y : 0 → 1 and Y : 0 → 1 leads to Z : 0 → 1.
Statement (b): If X ↑ Y and Y ↓ Z then X ⇓ Z.
Proof: If X : 0 → 1 then Y : 0 → 1 or Y is unaltered. When Y : 0 → 1 then Z : 1 → 0 or Z
is unaltered. If Y is unaltered then Z remains unaltered. Thus, we can see that either X ↓ Z or
X|Z. Note that X|Z can occur when no common network scenarios exist where X : 0 → 1 leads
to Y : 0 → 1 and Y : 0 → 1 leads to Z : 1 → 0.
Statement (c): If X ↓ Y and Y ↓ Z then X ⇑ Z.
Proof: If X : 0 → 1 then Y : 1 → 0 or Y is unaltered. When Y : 1 → 0 then Z : 0 → 1 or Z
is unaltered. If Y is unaltered then Z remains unaltered. Thus, we can see that either X ↑ Z or
X|Z. Note that X|Z can occur when no common network scenarios exist where X : 0 → 1 leads
to Y : 1 → 0 and Y : 1 → 0 leads to Z : 0 → 1.
Statement (d): If X ↓ Y and Y ↑ Z then X ⇓ Z.
Proof: If X : 0 → 1 then Y : 1 → 0 or Y is unaltered. When Y : 1 → 0 then Z : 1 → 0 or Z
is unaltered. If Y is unaltered then Z remains unaltered. Thus, we can see that either X ↓ Z or
X|Z. Note that X|Z can occur when no common network scenarios exist where X : 0 → 1 leads
to Y : 1 → 0 and Y : 1 → 0 leads to Z : 1 → 0.
Statement (e): If X|Y or Y |Z then X|Z.
Proof: If X|Y then X : 0 → 1 does not affect Y . If Y is unaltered then Z is unaltered regardless
of the relationship between Y and Z. Similarly, if Y |Z then Y : 0 → 1 does not affect Z. Thus,
any change in X does not effect any changes in Z. Hence, we have X|Z in either of the cases.
Property 3:
Suppose that we are given n + 2 variables X , Yi and Z, where i = 1, 2, ..., n, in network ℵ such
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that X is upstream of Yi and Yi is upstream of Z. Furthermore, suppose that Yi is neither upstream
nor downstream of Yj for i ̸= j and all paths from X to Z pass through one of the Yi’s. Here again
we consider three cases.
Statement (a): For each Yi, if X ↑ Yi and Yi ↑ Z or X ↓ Yi and Yi ↓ Z or X|Yi or Yi|Z then
X ⇑ Z.
Proof: Let yki represent the value of Yi when X = k. As X : 0 → 1 we have Yi : y0i → y1i . To
understand how all changes in Yi affect the value of Z we check how each Yi affects Z. We can
think of changing each value of Yi individually rather than simultaneously because the final value
of Z is determined by the final values of Yi. For i = 1 fix Yj = y0j for j ̸= 1. If X ↑ Y1 then we
will have Y1 ↑ Z or if X ↓ Y1 then we will have Y1 ↓ Z. In either case Z : 0 → 1 or Z remains
unaltered (using property 2). Also, if X|Yi or Yi|Z then Z remains unaltered (using property 2).
Next for each i ϵ 2, ..., n we fix Yj = y1j for j < i and Yj = y
0
j for j > i and observe how changes
in Yi affect Z. Applying a similar argument as for Y1 we see that either Z remains unaltered or
Z : 0 → 1. So, after considering all the Yk’s we see that either Z : 0 → 1 or Z remains unaltered
in response to X : 0 → 1. Hence X ↑ Z if there is at least one scenario where Z : 0 → 1 in
response to X : 0 → 1 or else X|Z.
Statement (b): For each Yi, if X ↑ Yi and Yi ↓ Z or X ↓ Yi and Yi ↑ Z or X|Yi or Yi|Z then
X ⇓ Z.
Proof: Making a similar argument as in the case of the proof of Statement (a) and using property
2 we can see that for X : 0 → 1 we have either Z : 1 → 0 or Z remains unaltered. Hence X ↓ Z
or X|Z.
Statement (c): For each Yi, if X|Yi or Yi|Z then X|Z.
Proof: Making a similar argument as in the case of the proof of Statement (a) and using property
2 we can see that for X : 0 → 1, Z remains unaltered. The reason is that any signaling due to a
change in the value of X does not reach Z as either X|Yi or Yi|Z. Hence X|Z.
Remark: Note that property 3 is a generalization of property 2. Also, in the property 2 and property
3 statements if we replace the ↑ by ⇑ and/or ↓ by ⇓ in the ‘If’ statements then the results still hold,
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as the arguments remain the same.
Definition: In a network ℵ, suppose X1, X2, ..., Xn are upstream of the variable Z. Then, we say
(X1, X2, ..., Xn) ↑ Z if two conditions are satisfied. First, changing any subset of the variables
X1, X2, ..., XN from 0 to 1 causes Z to either change from 0 to 1 or remain unaltered in any
network scenario. Second, for at least one network scenario in ℵζ there exists a subset of the
variables X1, X2, ..., XN which when changed from 0 to 1 forces Z to change from 0 to 1. Similarly
we define (X1, ..., Xn) ↓ Z. If in all possible network scenarios for all possible combinations of
changes in values of Xi the value of Z is unchanged then we write (X1, ..., Xn)|Z. We can define
the weaker version of the statement by simply relaxing the second condition for (X1, X2, ..., Xn) ⇑
Z and (X1, X2, ..., Xn) ⇓ Z.
Property 4:
Here we have three cases to consider.
Statement (a): Xi ↑ Z or Xi|Z for all i = 1, ..., n with Xi ↑ Z for at least one i if and only if
(X1, ..., Xn) ↑ Z.
Proof: This ‘only if’ part of the statement is easily proved by using an argument similar to that
used in proving case (a) of Property 3. Given Xi ↑ Z for all i = 1, ..., n we change each variable Xi
individually from value 0 to 1 or leave them unchanged and then we see that in each case Z : 0 → 1
or Z remains unaltered. Since all these changes are concordant with each other, we will see either
Z : 0 → 1 or Z remains unaltered. Thus as Xi ↑ Z for at least one i we have (X1, ..., Xn) ↑ Z.
Now given (X1, ..., Xn) ↑ Z, for a chosen i if Z is unchanged regardless of any change in the
value of Xi in any network scenario then we say that Xi|Z otherwise, we say Xi ↑ Z. Note that
for some i we must have Xi ↑ Z or else (X1, ..., Xn) ↑ Z would not hold.
Statement (b): Xi ↓ Z or Xi|Z for all i = 1, ..., n with Xi ↓ Z for at least one i if and only if
(X1, ..., Xn) ↓ Z.
Proof: This proof is exactly the same as that for case (a) with the only difference that the direction
of change for Z is reversed.
Statement (c): Xi|Z for all i = 1, ..., n if and only if (X1, ..., Xn)|Z.
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Proof: Again this proof is exactly the same as that for case (a) with Z remaining unchanged all
throughout the different cases.
Property 5:
Statement: For an upstream-downstream pair (X, Y ), if the parity of the number of negative gates
along any path from X to Y in network ℵ is fixed, then X has a fixed monotonic relationship with
Y or X|Y . Also, if the parity is even then X ⇑ Y and for odd parity we have X ⇓ Y . (sufficiency)
Proof: The proof is very simple. We start from X and move downstream towards Y analyzing the
relationship of X and the output of each gate G along any path from X to Y . We do not analyze
the relationship of the gate output with X unless all the gate inputs which are downstream of X
have their relationship analyzed with X . Observe that we can sequentially go through all the gates
as there are a finite number of such gates which lie on the paths between X and Y and also as
mentioned earlier the networks we are dealing with here does not have any feedback loops. We
can safely say that X ↓ X . This becomes our starting point.
Let the output of G be represented by Z. Let the inputs of G which lie on the path from X be
represented by Wi where i = 1, ..., k. Note that the parity of the number of negative gates along
any of the paths from X to each Wi must be the same or else we will have paths from X to Y with
different parity of the number of negative gates which contradicts our initial assumption. Also,
the parity number for the negative gates for all Wi’s must be the same. As we are sequentially
analyzing the gates and we know from property 1 and property 2 that negative gates will flip the
monotonicity (also weak monotonicity) direction, we can safely conclude that for all i = 1, ..., k
we either have X ⇑ Wi or X ⇓ Wi. Note that as the gate has multiple inputs, using property 1
we have Wi ↑ Z for positive gate G or we have Wi ↓ Z for negative gate G. Thus X ⇑ Wi for
positive gate G and X ⇓ Wi for negative gate G implies X ⇑ Z. Similarly X ⇓ Wi for positive
gate G and X ⇑ Wi for negative gate G implies X ⇓ Z. These follow from property 3. At the
end of any signaling path we will have Z = Y . Thus, we have monotonic relationship between X
and Y . Finally, we can see from the proof that if there is an even number of negative gates, then
there is an even number of flips in the monotonicity direction and using property 3 to combine the
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relationship along different paths, we have X ⇑ Y . If there is an odd number of negative gates,
then there is an odd number of flips in the monotonicity direction and hence X ⇓ Y . This proves
the sufficiency condition.
Property 6:
Statement: The fixed monotonic nature of a network is not affected by stuck-at-faults.
Proof: Note that introduction of stuck-at-faults can cause a path from an upstream variable X to
a downstream variable Y to be disconnected but the parity of the number of negative gates along
any path would still be the same. Hence, using property 5, the monotonic relationship between X
and Y either remains the same (i.e. X ⇑ Y or X ⇓ Y ) or X|Y in case all paths are disconnected
due to stuck-at-faults. Thus, the monotonic nature of the network is generally unaffected. Thus,
the monotonic nature of the relationship between X and Y remains the same or they satisfy X|Y
in the networks belonging to the class ℵζ .
Property 7:
Statement: If the parity of the number of negative gates for all existing paths from any particular
input of network ℵ to any particular output of network ℵ is constant, then the network ℵ is a fixed
monotonic network.
Proof: Consider any upstream-downstream variable pair (X,Y ), then they must have a constant
parity number for the negative gates along all paths; otherwise, we can always find a path P1
from an input variable to the upstream variable and a path P2 from the downstream variable to an
output variable of the network. These paths P1 and P2 combined with the paths between (X, Y )
give us paths between an input and an output variable with different parity numbers of negative
gates, which is not possible. So all upstream-downstream variable pairs (X,Y ) have a single
parity number of negative gates along all paths from X to Y . Thus using property 5 we see
all upstream downstream variable pairs (X, Y ) have a fixed monotonic relationship. Hence by
definition, network ℵ is a fixed monotonic network.
Remark: Note that to prove strict monotonic relationship, given fixed monotonic relationship be-
tween upstream variable X and downstream variable Y , all we need to do is to show one network
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scenario where a change in X causes a change in the value of Y . On the other hand, if it can be
proven that no such network scenarios exist then we have X|Y .
2.3 Application to MAPK signaling
The purpose of applying the concept of fixed monotonic Boolean networks to signaling path-
ways is to reduce the activity of cancerous cells. We will attempt to achieve that by regulating
the proteins and transcription factors using protein kinase inhibitors (or drugs) in such a way so as
to reduce the proliferation of cancerous cells. In our work, we use the MAPK signaling pathway
which plays a key role in the process of cell division. Before proceeding any further, we establish
the role of fixed monotonic Boolean networks with regard to the MAPK signaling pathway (Figure
2.1). For the sake of brevity henceforth the term signaling pathway and its corresponding net-
work equivalent ℵ will be used interchangeably. Note that as defined earlier, ℵ is also the primary
network of class ℵζ and hence has no stuck-at-faults. Hence a protein/transcription factor in the
signaling pathway corresponds to a Boolean variable in the network ℵ.
Observation 1: The Boolean network corresponding to the MAPK signaling pathway is a fixed
monotonic network.
Proof : We form a table to see whether the parity values of negative gates between each input and
output variable pair, with existent paths between them, are fixed or not. We indicate ‘even’ parity
with 0, ‘odd’ parity with 1, varying parity with x and n indicates input-output pairs with no paths
between them. This is shown in Table 2.2.
We see from Table 2.2 and property 7 that the MAPK network is indeed a fixed monotonic
network.
Observation 2: The drug targets D shown in Figure 2.1 and the output O of the MAPK pathway
are related either as D ⇑ O or as D|O.
Proof : If we trace the path(s) from any drug target location D to the output O we see that there
is always an even parity in the number of negative gates between the drug location to the output.
This is shown in Table 2.3, utilizing the same notation that was established earlier. Hence, using
property 5, we conclude that any single drug target D is linked to an output O as D ⇑ O or D|O.
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Figure 2.1: Boolean network corresponding to MAPK signaling with (a) representing the fault
locations and (b) showing the drug target locations (adapted and reprinted with permission of
Oxford University Press from [16]). (NOTE: The outputs marked in green are transcription factors
and the outputs marked in white are the reporter proteins)
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Table 2.2: Parity of the number of negative gates between each input and output of MAPK network.
Input
Output
FOS-JUN SP1 SRF-ELK1 SRF-ELK4 BCL2 BCL2L1 CCND1
EGF 0 0 0 0 0 0 0
HBEGF 0 0 0 0 0 0 0
IGF 0 0 0 0 0 0 0
NRG1 0 0 0 0 0 0 0
PTEN 1 n 1 1 1 1 1
The case of drugs with multiple target locations can be handled using property 4.
Here observation 2 can be generalized to state that the drugs drive all outputs to an acceptable
value. In MAPK as the acceptable value for the outputs are 0 we have D ⇑ O. If the acceptable
value for any of the outputs were 1 (i.e. if the output proteins inhibited cell division) then we
would require the signaling pathway to have D ⇓ O for all the drug target locations w.r.t the output
location O in order to have a property similar to that of observation 2.
Definition: An acceptable value for a protein is simply the desirable value of the protein state
which depends on the particular nature of the fixed monotonic network. This value can be 0 or 1.
A faulty value for a protein is the state opposite to that of the acceptable value. Thus, if the
acceptable value of a protein is 0 then the faulty value of the protein is 1 and vice versa.
In the context of MAPK signaling it is well known that the output transcription factors such
as FOS-JUN, SP1, SRF-ELK1, SRF-ELK4 stimulate cell proliferation. Furthermore, the output
reporter proteins BCL2, BCL2L1 report on apoptosis suppression while CCND1 reports on cell
proliferation. Hence in the absence of proliferation stimuli, the acceptable values for the outputs
are all 0 (i.e. inactive or downregulated state). It can be seen from Table 2 that the parity value
of the negative gates from the input proteins EGF, HBEGF, IGF, NRG1 to the output transcription
factors and reporter proteins is even but for the input PTEN it is odd. Thus, this agrees with the fact
that the input protein PTEN is a well-known cell division inhibitor and hence has an acceptable
value of 1 (active or upregulated state). The remaining input proteins encourage cell division and
hence have an acceptable value of 0. It is worth noting that the drug target locations as shown
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FOS-JUN SP1 SRF-ELK1 SRF-ELK4 BCL2 BCL2L1 CCND1
Lapatinib 0 0 0 0 0 0 0
AG825 0 0 0 0 0 0 0
AG1024 0 0 0 0 0 0 0
U0126 0 0 0 0 0 0 n
LY294002 0 n 0 0 0 0 0
Temsirolimus 0 n 0 0 0 0 n
in Figure 2.1 have acceptable values of 0. Hence when a protein kinase inhibitor targets these
positions it forces them to have an acceptable value by rendering the target protein inactive.
Observation 3: If a drug di drives an output oj to 0 by itself, then it would still drive the output to
zero (acceptable value) even in the presence of other drugs.
Proof : If we have other drugs we keep on adding them one by one after applying drug di. Note
that as di has already driven the relevant output to zero and the relationship between the drug target
and the output is given by D ⇑ O or D|O, we can see that adding other drugs and thereby forcing
the drug targets to zero would not cause the output to go from 0 to 1 as this would violate the
relationship D ⇑ O given by observation 2.
Observation 4: Consider combination of drugs d̂ and ď such that d̂ ⊆ ď. Then any output driven to
zero by d̂ will also be driven to zero by ď.
Proof : This basically follows from observation 3 since, if we add extra drugs to the cocktail of
drugs d̂ to get ď, the outputs which were already driven to zero by d̂ will stay at zero and hence the
result.
These observations will help us in reducing the number of drug combinations to be tested to
find the best possible drug combination which gives best possible output along with reduced side
effects. Here we assume that the number of drugs corresponds to the extent of side effects due
to chemotherapeutic treatment. In the next subsection, we will first see how these observations,
especially the second observation, can be used to reduce the number of test cases in our quest to
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find the best therapy while using the minimal number of drugs.
Remark: Note that observation 4 can be generalized, for fixed monotonic networks which satisfy
generalized observation 2, by using the term ‘acceptable value’ instead of ‘zero’ in the statement
and proof.
Definition: A clean friendly location (transcription factor/protein) in the network ℵ is a location
where the Boolean variable assumes an acceptable value if at least one of its immediate upstream
variables has an acceptable value.
A fault friendly location in a signaling pathway is a location where the Boolean variable as-
sumes a faulty value if at least one of its immediate upstream variables has a faulty value.
For example, in the MAPK network, the location 23 which represents the protein RPS6KB1
has an acceptable value of zero and so do the immediate upstream proteins at locations 11, 18 and
22. Thus, if one of the locations 11, 18 or 22 has a faulty value then the protein RPS6KB1 is also
upregulated or has a faulty value of 1. Thus, RPS6KB1 is a faulty friendly location. Similarly,
FOS-JUN is clean friendly as it will have an acceptable value (downregulated or 0) if either JNK1
has an acceptable value (downregulated or 0) or RPS6KB1 has an acceptable value (downregulated
or 0). Note that the proteins which have only a single immediate upstream protein like GSK3 at
location 19 or RHEB at location 21 can be categorized as both clean friendly and fault friendly.
Now keeping these definitions in mind, we look forward to using the properties of monotonic
networks in general and the signaling structure of MAPK pathway in particular to find the best
possible drug combinations using a limited number of test cases.
2.4 Drug intervention on MAPK signaling pathway
In this subsection we will show how the observations made in the previous subsection can
be used along with the MAPK pathway information to reduce the number of test cases. The
demonstration will be carried out using both synthetic data and experimental data.
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Table 2.4: Entries under drug combinations are output strings. TC1, etc. represents the extra test
cases needed to find the best drug combination dfinal.
Index Scenario Fault Drug combinations used for testing
dfinalnumber type locations dϕ d1 d2 d3 d4 d5 d6 dΣ
1 1 18 0111110 0111110 0111110 0111110 0111110 0111110 0111110 0111110 No drugs
2 1 19,23 0000111 0000111 0000111 0000111 0000111 0000111 0000111 0000111 No drugs
3 2 1,5,7,16,17 1111111 1111111 1111111 1111111 1000111 1111111 1111111 1000111 4
4 2 2,7,21,22,24 1111111 0000111 1111111 1111111 1000111 1111111 1111111 0000111 1
5 3 3,8,10,16,20 1111111 1111111 1111111 0111111 1000111 1111111 1111111 0000111 3,4
6 3 2,11,12,17 1111111 0111111 1111111 1111111 1000111 1111111 1111111 0000111 1,4
7 4 2,8,16,20,24 1111111 0111111 1111111 1111111 1000111 1111110 1111111 0000110 TC1
8 4 3,9,17,22,24 1111111 1111111 1111111 0111111 1000111 1111110 1111111 0000110 TC2
9 5 5,8 1111111 1111111 1111111 1111111 1000111 1111110 1111111 0000000 TC3
10 5 16,20,21 0111110 0111110 0111110 0111110 0000110 0111110 0111110 0000000 TC4
2.4.1 Synthetic Data
We assume in this test that all the inputs corresponding to growth factors i.e. EGF, HBEGF,
IGF, NRG1 are absent and the tumor suppressor protein PTEN is active (refer to Fig. 2.1). Thus, a
normal cell would force all the outputs to be ‘OFF’ or deactivated as the transcription factors (such
as FOS-JUN, SP1, SRF-ELK1 and SRF-ELK4) and reporter proteins (such as BCL2, BCL2L1
and CCND1) are expected to be inactive or downregulated in such a scenario. If there is a break-
down, i.e. a mutation which causes a breakdown in the MAPK signaling pathway, it should be
appropriately reflected as a stuck-at-fault in the network. Note that in Figure 2.1, for locations
X = {7, 19, 20, 24} we have X ↓ O where O represents any one of the 7 outputs. For the rest of
the locations we have X ↑ O. We consider only stuck-at-faults which force the output to be acti-
vated, thus leading to cancer. Hence for locations X = {7, 19, 20, 24} we consider stuck-at-zero
faults (marked in red in Fig. 1 (a)) and for the rest of the fault locations corresponding to values of
X = {1, 2, ..., 24}\{7, 19, 20, 24}, we consider stuck-at-one faults. So, if we say location X = 20
has a fault, it would imply that the value at the location X = 20 is stuck at 0.
For representing outputs, we simply use a string of binary numbers with 1 representing the ac-
tive state and 0 representing the inactive state. Thus the value 1000110 means that the output vector
[FOS-JUN, SP1, SRF-ELK1, SRF-ELK4, BCL2, BCL2L1, CCND1]=1000110. In this case, only
FOS-JUN, BCL2 and BCL2L1 are activated and the rest of the outputs are downregulated or inac-
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tive. If only SP1 is active then we write the output string as 0100000.
For the sake of convenience, the drugs Lapatinib, AG825, AG1024, U0126, LY294002 and
Temsirolimus are numbered from 1 through 6 in that order. For our testing purposes we represent
the case when no drugs are applied by dϕ. When all the six drugs are applied we represent it by dΣ.
For cases when at least one drug is applied but not all of them, we use the notation da,b,...,k where
{a, b, ..., k} is a listing of the drugs in the combination used. In our first round of tests we only
check the outputs of the network for the cases {dϕ, d1, d2, d3, d4, d5, d6, dΣ}. In other words, we
are initially considering the cases: no drugs used, all drugs used simultaneously, and all possible
drugs singly used. For any drug combination dΩ we represent the output as OdΩ. Hence OdΩ is
a binary string of length 7. We perform the combination ⊕ of two or more such output strings
such that the resulting string has an acceptable value in the ith bit if at least one of the original
strings had an acceptable value in the ith bit or else the ith bit has a faulty value. In case of MAPK
this is implemented simply by using the ‘AND’ operator on the individual string positions. Thus
we have 0011001 ⊕ 0000111 = 0000001. For any two output sequences Oda and Odb if Odb has
acceptable values at all the locations Oda has acceptable values in, and acceptable values in a few
more positions where Oda has faulty values, we write Oda < Odb. We can use the symbol ≤
instead of < where a possibility of equality exists. Now a total of 5 scenarios can occur when we
test the output for the cases dϕ, d1, d2, d3, d4, d5, d6, dΣ. They are;
Scenario 1: Odϕ = OdΣ
Scenario 2: Odϕ ̸= OdΣ & Odi = OdΣ for some i ϵ {1, 2, 3, 4, 5, 6}
Scenario 3: Odi ̸= OdΣ for any i ϵ {1, 2, 3, 4, 5, 6} & Odi⊕Odj = OdΣ for some i, j ϵ {1, 2, ...., 6}
Scenario 4: ⊕iϵSOdi = OdΣ only for one or a few S ⊆ {1, 2, 3, 4, 5, 6} where |S| > 2
Scenario 5: ⊕iϵSOdi < OdΣ where S = {1, 2, 3, 4, 5, 6}
Note that for any signaling pathway, which is a fixed monotonic Boolean network and satisfies
the generalized observation 2, we will have these five scenarios assuming that we are only using the
drug combination dϕ, dΣ and di where i ϵ {1, 2, ...., k} where k > 2 is the number of drugs available
to target the pathway. The reasoning is as follows. On basis of generalization of observations 4
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and definition of the operation ⊕ we can say that Odϕ ≤ Odi ≤ OdΣ and ⊕iϵSOdi ≤ OdS where
S ⊆ {1, 2, ...., k}. Thus we obtain Odϕ ≤ Odi ≤ Odi ⊕ Odj ≤ ⊕kϵSOdk ≤ OdΣ where i, jϵS
and |S| > 2. Thus, looking at this inequation with four inequalities and five expressions we come
up with the five scenarios. In scenario 1 we have Odϕ = OdΣ thus forcing all the intermediate
inequalities to become equality. In scenario 2 we have Odi = OdΣ for some i and Odϕ < OdΣ. In
scenario 3 we have Odi ⊕ Odj = OdΣ for some i, j whereas Odi < OdΣ for all i. In scenario 4
we have ⊕iϵSOdi = OdΣ for some S where |S| > 2, S ⊆ {1, 2, ...., k} and Odi ⊕Odj < OdΣ for
all i and j. Finally in scenario 5 we have ⊕iϵSOdi < OdΣ for all S ⊆ {1, 2, ...., k}.
Now we describe the procedure which automates most of steps to identify the best possible
drug combination(s) given the initial round of tests. After the initial round of tests in some cases
a second round of tests might be needed, which forms the manual part of the procedure, as we
shall see later. The steps have been depicted by a flowchart which is shown in Figure 2.2. Here,
we will focus on and use examples based on the MAPK signaling pathway shown in Figure 2.1
to find the best possible drug combination dfinal. We will see that the dfinal is indeed the best
possible combination satisfying our requirements by looking at the outputs for all the possible
drug combinations.
Please note that these steps can be applied to any signaling pathway with any input values as
long as it satisfies the condition for fixed monotonic Boolean network and the generalized obser-
vation 2 in the previous subsection.
Steps to identify the best drug combination
Step 1: If the test cases belong to scenario 1, 2 or 3 then the best possible drug combination
dfinal can be computed only by using the general properties of fixed monotonic Boolean network
otherwise proceed to step 2.
Implementation and Explanation: Here we assume that the signaling pathway information along
with the drug data for the relevant network is already available. The observed output values are
manually entered.
Clearly drug combination dΣ gives the best output on the basis of observation 4. Scenarios
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Figure 2.2: Flowchart depicting the method to find the best drug combination
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1, 2 and 3 offer the best drug combination in a straightforward manner. For scenario 1, the best
combination is giving no drugs. On the basis of observation 4, clearly any subset of drugs cannot
further downregulate the active outputs; hence, it is best not to give any drugs in this case and thus
there is no possible chance for any side effects. Thus for scenario 1, we have dfinal = dϕ.
If the test results satisfy scenario 2, then we need at least one drug to achieve the best output.
Hence the drug ‘i’ is the best possible drug combination since it gives the best output and also
requires the least number of drugs. Thus, for scenario 2, we have dfinal = di. In the case of
scenario 3, we can clearly see that no single drug is able to give the best result in terms of output
downregulation but the two drugs individually combined downregulate all the outputs to give the
best result. Hence the best possible combination of drugs is the combination of the two drugs di
and dj . Thus dfinal = di,j for scenario 3. We can see examples of these three scenarios in Table
2.4, by looking at the dfinal for the first six mutated networks.
Now for scenarios 4 and 5, we are unable to obtain a generic result, that holds for any fixed
monotonic Boolean network satisfying a generalized form of observation 2. Instead, we will also
have to exploit the particular network structure along with the fixed monotonic nature of the path-
way.
Step 2: Identify the clean locations (i.e. the proteins which are unaffected by cancerous mutations).
Then proceed to step 3.
Implementation and Explanation: The identification of clean locations is carried out as follows.
We assume a fault in the location x (say) and then trace down the network to the terminal outputs.
Since the location x has a faulty value this causes the downstream locations to assume faulty values.
This may contradict with the actual test results where some of the outputs may have acceptable
values. In this case, we would have a contradiction and hence our initial assumption about location
x would be wrong. Thus, we deduce that the location x is clean. Using this method, we identify
the clean locations. This idea is utilized in two ways as follows:
a) We take into account a test case (A single test case comprises of all the observed outputs
for a single drug combination) out of the tests already performed on the cell lines (we have a
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total of eight test results in our case for the synthetic MAPK data) and see which of the output
nodes have acceptable values. Assume that a location x has a mutation and then use the Boolean
network (MAPK in this case) to see if it predicts a faulty value in the output which in reality has
an acceptable value. If it does, then the actual test does not agree with the prediction which means
that our assumption was wrong. This implies that location x is a clean location and does not have
any mutation.
For example, in mutated network numbered 7 in Table 2.4, let us look at the response of MAPK
cell lines to the drug combination d5. Here the output protein CCND1 has an acceptable value of
0. Hence, we can use this information to deduce that location 10, 11, 12 and 19 must be clean or
otherwise they would lead to a faulty value in the output CCND1 which actually has an acceptable
value.
b) Let us assume that in a test using the drug combination dα we observe an acceptable value
in the output node oi but a faulty value in the output node oj while for the test using the drug
combination dβ we observe a faulty value in oi but an acceptable value in oj . This would mean
that out of all the locations in the signaling pathway targeted by the drug combination dβ but not
targeted by the drug combination dα, we must have some locations which have faulty values when
we are testing using the drug combination dα. These faulty values would lead some of the signal
paths to have faulty values. We could eliminate these faulty signal paths from the list of paths
between target locations of the drug combination dα and the output oi while determining clean
locations.
Let us look at an example to better understand this idea. Consider the mutated network num-
bered 7 in Table 2.4. In this case, for the drug combination d1 output node FOS-JUN (o1) has an
acceptable value but output node CCND1 (o7) has a faulty value. On the other hand, for the drug
combination d5, the output node o1 has a faulty value and the output node o7 has an acceptable
value. This would imply that when we are testing using the drug combination d1 the target location
of d5 (not targeted by d1) i.e. location 9 must have a faulty value which leads o7 to have a faulty
value. Faulty value at the location 9 implies a faulty value at the location 23 when we are applying
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the drug combination d1. This would lead us to the conclusion that the location 15 must have an
acceptable value or else FOS-JUN would be upregulated (i.e. have a value 1) which is not the case.
Only a clean location can have an acceptable value hence location 15 does not have any cancerous
mutations. Similarly, locations 3, 5, 6, 13 and 14 must be clean or be mutation free.
Step 3: Identify drugs which are essential to be considered for treatment of patient. Then proceed
to step 4.
Implementation and Explanation: We can eliminate the drugs which we deem unnecessary in two
situations. This algorithmic step is explained below.
a) In this case we will show how a drug or a combination of drugs can be eliminated once it
is determined that the target locations of the drug never has a faulty value due to mutations in the
signaling pathway.
For example, again looking at mutated network 7 we saw in the previous step that location
3 is a clean location. Upstream of this location we only have input values which are already set
to acceptable values. Hence location 3 always has an acceptable value. Thus, the drug AG1024
which targets only location 3 is unnecessary and can be dropped from the list of drugs which are
to be considered for treating the patient.
b) In the second situation if a drug completely overlaps the targets of another drug then the
overlapped drug can be removed from the list of drugs to be considered for treating the patient
as the activity of the overlapping drug subsumes that of the overlapped drug. This follows from
observation 4 in the previous subsection.
As an example, consider the drug AG825 which targets location 1 and 4 and consider the drug
Lapatinib which targets 1, 2 and 4. We can clearly drop the drug AG825 from the list of drugs to
be considered for treatment of the patient.
Step 4: Calculate which outputs should have acceptable value for each available drug combination
(the ones not tested involving the essential drugs from step 3). Then proceed to step 5.
Implementation and Explanation: There are two cases which need to be considered in this step.
Each case is illustrated by an example below.
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a) Suppose a tested drug combination dα drives the output node oi to an acceptable value. Now
consider an untested drug combination dβ . Represent all the target location(s) of drug combination
dα which does not overlap with target location(s) of dβ by tα. We know from the signaling pathway
information that the target locations of dβ cut off all paths between tα and output node oi. If we
apply a drug combination which includes all the drugs in dα and dβ then definitely output node oi
will be driven to an acceptable value on basis of generalized observation 4. Removing the drugs
from the pathway location tα should not have any effect on output node oi as there is no available
path between tα and the output node oi through which any changes in signal value at tα can be
transmitted. Thus applying the drug combination dβ only we can say that output node oi is driven
to an acceptable value.
For example assume drug AG1024 drives output o5 (i.e. BCL2) to an acceptable value but the
drugs U0126 and LY294002 do not drive o5 to an acceptable value when used individually. This
can actually happen if the MAPK pathway has a single fault at the location 3 (target of AG1024).
In this case looking at the structure of MAPK we can easily deduce that the drug combination
involving the drugs U0126 and LY294002 together will drive o5 to an acceptable value. The
reasoning is that these two drugs force the locations 9 and 17 to an acceptable value and also cut
off all possible paths between the location 3 and the output o5. Thus, based on observation 2
and the fact that the two locations through which the acceptable value would be transmitted from
the location 3 to the output o5 have been forced to 0 we can safely deduce that o5 is driven to 0
(acceptable value) by the drug combination U0126 and LY294002 together.
b) In this case using observation 4 and the operation ⊕ defined earlier we can determine which
outputs have acceptable values (0 in case of MAPK). Based on this we can determine which of
the clean locations determined in step 2 must have acceptable values. This determination of clean
locations with acceptable values is done by identifying fault friendly locations which have ac-
ceptable values. This implies that immediate upstream locations must have acceptable values by
definition of fault friendly location. We repeat the process over and over again by identifying new
fault friendly locations with acceptable values and stop when we cannot find any new fault friendly
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locations with acceptable values. We assume that the rest of the locations have faulty values. Then
using the structure of the fixed monotonic network, we compute which outputs have acceptable
values. As this is a worst-case scenario where we are forcing maximum locations to have faulty
values the outputs which are computed to have acceptable values must have acceptable values (0
in our case of MAPK).
Consider for example the same drug combination U0126 and LY294002 described in the pre-
vious case (a). An acceptable value at the location o5 forces the location 23 in MAPK to have an
acceptable value when the two drugs are applied which would mean the output o1 (i.e. FOS-JUN)
must be 0 (an acceptable value) because o1 is a clean friendly location.
Step 5: Identify the combination with the least number of drugs which gives the best output on
basis of step 4. Then proceed to step 6.
Implementation and Explanation: We check if any untested drug combinations considered in step
4 attains the best possible output. This is done by comparing outputs obtained in step 4 with the
best possible output i.e. OdΣ and then choosing the one combination involving the least number
of drugs which provides the best possible output. Let us represent this combination by ‘db’ and the
total number of drugs in the combination by ‘k’.
Step 6: Identify the possible drug combination candidates with less than k drugs which could give
the best output. Then proceed to step 7.
Implementation and Explanation: For this step we look at all untested combinations with less
than ‘k’ number of drugs where ‘k’ is defined in step 5. Once the drug combinations have been
identified let us represent the set of these combinations by St. For each combination in St we
see which output nodes have faulty values, on basis of step 4, but have acceptable values in the
best output OdΣ. Then we try to see if there is a possibility of the drug combination achieving an
acceptable value in those output nodes.
The implementation is explained using the mutated network numbered 8 in Table 2.4 as fol-
lows. We know drug combination (let’s say d45) composed of LY294002 (d5) and U0126 (d4)
would give an output 1000110 based on step 4. Best possible output is 0000110. So, the output
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Table 2.5: Second round of experiments. Here Sp represents the set of drug combinations to
be tested. dbest represents the drug combination identified in step 7 of the algorithm which will
certainly give the best output. dfinal is the drug combination which is finally identified as the best
combination to be used for the cancer patient following the protocol for treatment.
Extra Experimental
Test Sp Output dbest dfinal
Cases Values
TC1 4,5 1000110 1,4,5 1,4,5





TC4 4,6 0000000 1,2,3,4,5,6 4,6
node o1 (i.e. FOS-JUN) is supposed to have an acceptable value but has faulty value based on
step 4. Our aim is to see if drug LY294002 and U0126 combined can drive o1 to an acceptable
value. In this case we see that downstream paths from d5 and d4 combine at location 23 which is
upstream of o1 and is a fault friendly node. Thus it is entirely possible that the drug combination
d4,5 forces location 23 to have an acceptable value whereas d4 and d5 could not force location 23
to have an acceptable value themselves due to the way fault friendly nodes behave. As location 23
is upstream of o1, an acceptable value at location 23 would lead o1 to have an acceptable value. In
general, networks having an acceptable value at a fault friendly location where paths from two or
more drugs first combine could lead the downstream output node to assume an acceptable value.
Thus, we basically assume an acceptable value in the output node being considered if there is a
fault friendly node upstream of it where paths from the two or more drugs in the drug combination
being considered combine (eg. paths from LY294002 and U0126 combine at fault friendly node
at location 23). Now with the updated output list for the combinations in St we see which of the
outputs are same as the best possible combination. These drug combinations which are possible
candidates to have best possible outputs along with the drug combination db obtained in step 5 are
represented by the set Sp.
Step 7: Identify the drug combination dbest with the least number of drugs which is predicted to
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produce the best output just on the basis of the results of applying the operator ⊕ on the tested
drug combinations. Remove this drug combination from the set Sp or simply put Sp = Sp\dbest
(popularly used notation for set subtraction in set theory).
Implementation and Explanation: In order to find dbest for scenario 4 we can find a drug combi-
nation with the least number of drugs which gives the best output on basis of the operator ⊕. For
scenario 5 we simply use the drug combination dΣ.
Clearly mutated network numbered 8 in Table 2.4 is an example of scenario 4. Here we can see
that dbest is the drug combination involving d3,4,5. After step 6 of this algorithm Sp = {d3,4,5, d4,5}
for test case 8. As dbest = d3,4,5 we reevaluate Sp by subtracting dbest from Sp. Finally we have
Sp = d4,5 and dbest = d3,4,5.
Similarly, we can see that the mutated network numbered 10 in Table 2.4 is an example of
scenario 5. Hence the drug combination dbest is simply the combination dΣ. After step 6 of the
algorithm Sp = d4,6. Finally after evaluating this step we have Sp = d4,6 and dbest = dΣ.
Note that the value of dbest found in this step of the algorithm need not be the same as the value
of db found in step 5. This is because, computation of dbest makes use of the operator ⊕ and the
experimental results only unlike db, whose computation also makes use of the signaling structure
of the network.
Step 8: Run a final round of experiments involving the drug combination identified in Sp. Proceed
to step 9.
Implementation and Explanation: This is the manual part of the procedure which involves testing
the drug combinations in set Sp on the mutated network.
We can see in Table 2.5 the output strings for the mutated network 7, 8, 9 and 10 (refer to Table
2.4) in the second round of testing.
Step 9: If some combinations in Sp actually achieve the best output in the testing then choose the
one with least number of drugs dfinal and Stop. If not proceed to step 10.
Implementation and Explanation: Here we can see in Table 2.5 that for mutated network numbered
9 and 10 (refer to Table 2.4), corresponding to test cases TC3 and TC4 respectively, some drug
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combinations in Sp achieve the best output thus providing us the dfinal values.
Step 10: If none of the drug combinations in Sp actually produce the best output then we set
dfinal = dbest where we computed dbest in step 7 of the algorithm. Stop.
Implementation and Explanation: Here we can see in Table 2.5 that for mutated network numbered
7 and 8 (refer to Table 2.4) , corresponding to test cases TC1 and TC2 respectively, we find the
dfinal values in this step.
The synthetic data set (as shown in Table 2.4 and Table 2.5) has been generated on basis of the
prior knowledge about the MAPK pathway. The drug combination dfinal (as shown in Table 2.4
and Table2.5) decided following the steps mentioned above can then be administered to a cancer
patient. The results of the steps above are shown in Table 2.4 and Table 2.5. Note that in Table 2.4
for the first six mutated networks we can immediately identify the best drug combination in the
first step of the procedure as they belong to one the scenarios 1, 2 or 3. For the remaining mutated
networks (i.e. 7, 8, 9 and 10) we have to go through all of the steps described above. Thus, for
the last four mutated networks the drug combinations, Sp (shown in second column of Table 2.5)
which are possible candidates for best drug combination are identified. In fact, the goal of the steps
2 through 7 is to help identify the smallest possible set Sp which will help us in identifying the best
drug combination with certainty. The actual experimental results for the drug combinations Sp are
provided in the third column of Table 2.5. The fourth column of Table 2.5 lists the combination
which is supposed to give the best output as computed in the seventh step.
Thus, we see that for handling scenarios 4 and 5, we need to use the structure of the MAPK
signaling pathway along with the properties of the fixed monotonic Boolean network class. It is
worth noting that the drug combination db which was identified in step 5 of the algorithm should
definitely give the best possible output if signaling pathway behaves as a perfect Boolean network.
However, we do include db in the set of drug combinations Sp to undergo a final round of test-
ing to see which combinations actually give the best output. This is because the cell signaling
pathways are less than perfect examples of Boolean circuits, even though using logic gates are an
efficient way to represent various protein-protein interactions. The properties of fixed monotonic
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Table 2.6: Expression values of reporter genes and transcription factors for initial test case.
Housekeeping SRF-ELK SP1 reporter
gene reporter gene genes
GAPDH EGR1 cMYC JUN IRF3
No drugs 1 1 1 1 1
LY294002 1 0.795536 0.411796 0.946058 0.806642
LY294002+U0126 1 0.386891 0.291183 0.31864 0.353553




SP1gene reporter gene genes
GAPDH EGR1 cMYC JUN IRF3
No drugs 1 1 1 1 1 1 1
LY294002 1 1 1 0 1 1 1
LY294002+U0126 1 0 0 0 0 0 0
Boolean network still hold for the Boolean analogues of the signaling pathways. Hence, we can
be much more certain that the drug combination dbest computed in step 7 of the algorithm will
definitely provide the best output in an experimental set up. In the next subsection we will further
explain the above statements as we deal with real world data from actual cell lines in the following
subsubsection.
The dfinal obtained for the 10 mutated networks are actually the best possible drug combina-
tion. This can be easily verified by simply checking that no other drug combination with lesser
number of drugs gives the best output. This is immediately clear for the networks 1, 2, 3, 4, 5,
6, 9 and 10 from Table 2.4 and Table 2.5. For networks 7 and 8 we simply check the outputs
corresponding to the drug combinations with two drugs and find that none of these combinations
actually give the best output.
2.4.2 Experimental Data
To illustrate the usefulness of the idea of fixed monotonic Boolean networks we perform a
simple experiment [26] on actual cell lines. For this purpose, we choose normal adult fibroblast
cell lines. These cell lines were grown in Fibroblast Basal Medium (ATCC) in 60 mm tissue cul-
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ture petri dishes till confluence. After this the cells were exposed to Dulbeccos modified Eagles
medium-F12 (DMEM/F12) (Atlanta Biologicals) which was supplemented with 0.2% fetal bovine
serum (Atlanta Biologicals) for 4 days. Every day after washing with phosphate buffer solution
(PBS) the medium was changed. The cell cultures were incubated in a 5% CO2 incubator at 370C.
After this they were exposed to DMEM/F12 further supplemented with 0.2% FBS and 100µM
Anisomycin for a period of 30 minutes. Anisomycin is a protein synthesis inhibitor which acti-
vates the MAPK signal transduction network and keeps it responsive to kinase specific inhibitors
[27, 28]. Further it also cuts any feedback path that has a protein synthesis step in it. The tissue
culture petri dishes were then grouped into 4 groups. After initially exposing them for 30 minutes
to Anisomycin each group was exposed to DMEF/F12 supplemented with 20% FBS, 100µM Ani-
somycin, 50µM of LY294002, and/or 10µM of U0126. 2 Genes which have response elements
to transcription factors SP1 and SRF-ELK1/4 were quantified using real time PCR and the delta-
delta method [29] with GAPDH being used as a reference gene or the housekeeping gene. The
group which has no drugs applied is used as the control. EGR1 the reporter gene for transcription
factor SRF-ELK [30] is measured. For the transcription factor SP1 the reporter genes measured
are cMYC, JUN, IRF3 [31, 32, 33]. Hence, we have a total of 4 observed reporters genes whose
expression values are computed as shown in Table 2.6 and 2.8. In our case we use a simple thresh-
old for expression values to decide if a gene is active or inactive. The threshold is set at 0.5. Any
value more than 0.5 is assigned a value of 1 or else it is assigned a value of 0. In a more realistic
scenario, this value could also be set by taking input from doctors treating cancer patients. As SP1
has three reporter genes, to decide the Boolean state of SP1 we pick the state which appears most
frequently for its reporter genes. In this case, the MAPK pathway has all growth factors present
and PTEN is active. Hence all inputs to the network are set to 1.
As for the present experiment, we assume we have only two drugs U0126 and LY294002.
In the first set of tests, we run the tests with no drug case, LY294002 only and the best output
2Note that since we have only two drugs here, if we proceeded by testing with no drugs, then with one drug at a
time, and then finally with both the drugs, we would have exhaustively covered all possible cases, in the first round
itself. Accordingly, to keep the problem interesting, we initially consider only one of the cases where a single drug
has been applied.
34
Table 2.8: Expression values of reporter genes and transcription factors for the second round of
tests.
Housekeeping SRF-ELK SP1 reporter
gene reporter gene genes
GAPDH EGR1 cMYC JUN IRF3
U0126 1 0.812252 0.397768 0.68302 0.45376




SP1gene reporter gene genes
GAPDH EGR1 cMYC JUN IRF3
U0126 1 1 1 0 1 0 0
case involving LY294002 and U0126 as shown in Table 2.6 and Table 2.7. Now using the 3 steps
described in the previous subsection we see that, in Table 2.7 the best output is not achieved in
either the no drug case or when LY294002 is applied. Thus, it does not satisfy scenario 1 or 2.
As we do not have the output data for application of U0126, we can say that this test case does
not satisfy scenario 3 either. It thus belongs to scenario 4 or 5. Now going through the steps
described earlier we have in step 5, db = dU0126. Finally, in step 7 we have Sp = {dU0126} and
dbest = dLY 294002,U0126. Then we run the experiment on the drug combinations of Sp. These results
are shown in Table 2.8 and Table 2.9. As dU0126 does not give the best output we will finally choose
dbest i.e. dLY 294002,U0126 as the best drug combination to be used for treatment.
The dfinal obtained for the cell lines is also the best possible. This is easily seen by looking at
Table 2.10 observed values column.
3The automated portion of the steps described in the previous subsection under subsubsection titled “synthetic data"
is implemented in a manner such that it can handle experimental data as long as we have the experimental results from
the application of dϕ, dΣ and some of the di’s. If results for some di’s are missing it would not impede the working of
the procedure. Also, the input values to the signaling network should not affect the working of the algorithm as long
as they are known.
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Table 2.10: Comparison of Expected and Observed Values.
Expected values Observed values
SRF-ELK SP1 SRF-ELK SP1
No drugs 1 1 1 1
LY294002 1 1 1 1
U0126 0 0 1 0
LY294002+U0126 0 0 0 0
2.5 Discussion
The primary goal of the section is to use minimal number of test cases to identify the best
possible drug combination for the patient thus making the whole process more cost efficient and
time efficient. Hence to achieve the goal of reduction in the number of test cases, the properties of
fixed monotonic networks is exploited to help identify the best drug combination using a smaller
subset of test cases. As the general monotonic properties associated with the network is not enough
to help identify the best drug combination in some scenarios, we further exploit the signaling
structure of the individual pathway as shown in the procedure in the previous subsection to obtain
the minimal set of test cases Sp in order to fulfill our purpose.
In simulated data we have used a total of six kinase inhibitors on the MAPK pathway. Hence
the total number of test cases involved in brute force experimentation is 26 = 64. In the first three
scenarios, clearly, we just need only a total of 8 cases to give us the best drug combination which
will not only produce the best output but also be the one with the least possible side effects. The
remaining two scenarios could require a few more test cases depending on the actual mutation
and the signaling network structure. This is clearly seen in the previous subsection. Thus, the
properties of the fixed monotonic Boolean network class is the crucial ingredient that permits a
reduction in the number of test cases, no matter what the actual network structure is as long as
the network belongs to that class. This is especially evident for the first three scenarios considered
where we can clearly see that the number of test cases for n drugs is simply n + 2 which is linear
w.r.t. n as opposed to the total number of available drug combinations 2n which is exponential in
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nature. However, as scenario 4 and 5 need us to exploit the signaling structure of the pathway this
method sometimes can be limited by the accuracy of representation of signaling pathways using
Boolean networks as we see in the experimental data set. Also, this adds a varying number of
drug combinations to the test set depending on where the mutations are located in the network.
Thus, one scope of improvement in the future would be to further exploit the monotonic nature
of networks and reducing the utilization of signaling pathway structure while deducing the best
possible drug combination like we did for scenarios 1, 2 and 3.
From the experimental results in the previous subsection, we see that the properties of fixed
monotonic Boolean networks hold even in real life scenarios and can be exploited as such. Indeed,
from Table 2.7 and Table 2.9 it is clear that a subset of drugs drives fewer components of the
output to zero as compared to a superset of drugs. Also looking at the expression values in Table
2.6 and Table 2.8 we can see that expression values of the output is always lower for a superset of
drugs as compared to a subset of it. Thus, the advantage of using properties of fixed monotonic
Boolean networks instead of just using Boolean representation is that it is robust to the choice of
threshold for determining the binary value from the expression data. The reason behind this is
that the MAPK signaling network which is derived from the MAPK signaling pathway diagram
still satisfies property 7 given in an earlier subsection. The negative gates are introduced only
where a signaling protein inhibits the immediate downstream protein. Hence, if we look at any
signaling path from any input to any output, the parity of the number of inhibitory signaling steps is
exactly the same as the parity of the number of negative gates in its corresponding digital signaling
diagram. So, our method based on properties of fixed monotonic Boolean network still holds good
even though we introduce loss of information when we quantize continuous expression data into
digital data.
Using the threshold 0.5, we computed the observed states for the outputs SP1 and SRF-ELK. In
the Table 2.10, the expected values have been calculated by taking into account the fact that all the
inputs corresponding to growth factors in the MAPK signaling network are present and the tumor
suppressor input PTEN is also present. The observed and expected values diverge for SRF-ELK
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when the testing is done using only drug U0126. One reason for observed values for SRF-ELK
not agreeing with the expected value could be that signaling pathways do not behave exactly as
Boolean networks. To better understand this, let us look at the behavior of SRF-ELK and SP1 when
the drug U0126 is applied. The median value for the expression levels of the SP1 reporter genes lies
close to 0.45. Thus, looking at the signaling pathway we can say that, in all probability expression
level of ERK1/2 also lies close to 0.45 as SP1 depends only on ERK1/2. Now the protein RPS6KB1
is expected to have a higher expression level as the input growth factors are present. SRF-ELK is
determined by the combined effect of both RPS6KB1 and ERK1/2. Thus, as expression level of
ERK1/2 is close to 0.5 albeit less than it and RPS6KB1 has a high expression value we would
expect a higher level of expression for SRF-ELK. However, since we are converting expression
values into binary values simply by using a threshold, the information that the value of ERK1/2
is close to 0.5 is not utilized here and hence our observed and expected values do not match up.
Perhaps such an issue can be prevented by using a slightly stronger concentration of drugs which
would perhaps downregulate the outputs further instead of the current expression values which lie
close to the transition value of 0.5. The strength of drugs applied in such a context can be a topic
of interest for research. Another reason for the observed value and expected value not matching
up might have to do with biological noise inherent in such experiments. Such problems due to
noise can be avoided by looking at expression values of few more reporter genes for SRF-ELK or
by taking multiple reading of the same reporter gene to help reduce biological noise present in the
readings. Note that in the case of SP1 for which expression value readings from multiple reporter
genes were taken, the expected and observed values match up completely. Nevertheless, we can
see that prediction made on basis of assumptions of a perfect Boolean circuit might lead to faulty
results in certain cases. This is also the reason why the drug combination db identified in step 5
of the procedure to give the best output is experimentally tested as a part of the set Sp. However,
the drug combination dbest computed in step 7 only using the monotonic properties of MAPK still
works and hence it need not be tested to guarantee its outcome in terms of the pathway output. This
is one of the major advantages of utilizing the properties of fixed monotonic Boolean network.
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The computational complexity of the automated portion of the procedure (step 1 - step 7) has
not been considered in the current work, as our primary focus has been to reduce the number
of tested drug combinations needed to identify the best drug combination. This makes sense as
testing of drug combinations is much more time consuming compared to the computational time
associated with running the automated process for a single signaling pathway. However, as we try
to create a unified picture of the signaling in various cellular pathways to better target cancer it will
become much more pertinent to try and find ways to reduce computational complexity.
In our work the proposed method has been applied to pathways which satisfy the properties of
fixed monotonic network and thus can be modeled as such. There may be many pathways which
do not behave as a fixed monotonic network. In such cases we could make use of our method by
looking at a portion of the pathway which might behave as a fixed monotonic network. This will
allow us to apply our method and identify the best possible drug combination which might be used
for that sub pathway. Another way to deal with this problem, would be to extend our method to
monotonic networks where we do not simplify the network as a digital circuit but rather make use
of the monotonic relationship between inputs and outputs of the pathway. This would definitely
increase the scope of our method.
Some other work such as [16, 26] have considered the problem of identifying the best possible
drug combination for a cancer patient. In [16] they have considered networks with single mutations
only and best drug combination is identified by categorizing different mutations into different
classes on basis of their response to a test input and then mapping each fault locations onto the
appropriate drug combination. In this section the idea is not to identify mutations or categorize
mutated networks but rather use results from a smaller number of test cases to try and predict
output for other drug combinations and utilize that to find the best drug combination. Also, our
method is designed to deal with signaling pathways with multiple mutations as compared to [16].
The method as developed here can be used for treating cancer where a single type of mutated
signaling pathway is present in all the cells making up the cancerous tissue. However, more often
than not, and especially in the case of advanced disease, the cancerous tissue is heterogeneous in
39
nature. In other words, they have different kinds of mutated signaling networks. Work on how
to identify best possible drug combination for such heterogeneous tissue has been considered in
[26] and a refined version is presented in the section 3 [4]. Although this section deals with het-
erogeneous networks but it requires a prior knowledge of the mutated networks present in the
heterogeneous mix. In this section we do not assume any prior knowledge of the mutation loca-
tion whereas we deal with homogeneous cancer tissue. Thus, a possible direction of research is
to develop methods to deal with heterogeneous cancerous tissue when the mutations are apriori
unknown. This approach has been dealt with in section 4 [5].
Another aspect which needs to be considered is when mutations introduce new signaling con-
nections into the existing pathway structure. This is better represented by bridging faults [17].
Finally, we have considered only networks where there are no feedback loops but in certain path-
ways feedback is present. Preliminary work on behavior prediction of such feedback networks has
been considered in [34]. In the next two sections, this aspect is implicitly taken care of. Mak-
ing substantial progress on each of the problems mentioned above should go a long way towards
bringing our results to the domain of practical implementation.
2.6 Conclusion
In this section, we have investigated the properties of fixed monotonic Boolean networks and
tried to exploit the monotonic nature of such pathways. These properties were applied to digital
equivalents of cellular signaling pathways. We have shown how these properties can be utilized
in combination therapy design for cancer to efficiently find the best possible drug combination
with minimal side effects from the available spectrum of drugs. Another interesting feature of this
method is that we do not need to actually identify exact mutations but can instead focus on the
output of the signaling pathways which is what matters while treating cancer. The advantage of
looking at outputs rather than exact mutations is that even if there is an unknown secondary signal-
ing mechanism through which the mutation might affect the outputs our method would intrinsically
take that into account as we are trying to modify the outputs instead of targeting particular muta-
tions. As we also saw in the previous subsection there are some issues when Boolean network
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models are used for signaling pathways. If certain protein-protein interactions are unknown then
Boolean network model is unable to accurately capture the essence of the pathway and some steps
in the presented algorithm which requires a perfect knowledge of the Boolean structure would not
provide us with accurate results. Thus, one of our goals for future improvements would be to make
our method more dependent on monotonic properties of the network rather than knowing the ex-
act details of the protein-protein interactions to avoid this problem. Also, another issue involving
this method is with regards to choosing a threshold. As was mentioned earlier the quantization of
expression values to two states leads to loss of information in some cases, especially in the cases
where the expression value lies close to the threshold. Perhaps in the future to avoid this issue in-
stead of a sharp threshold we could define a buffer region where expression values are not mapped
to either the state 0 or 1 and the method only utilizes the outputs which have a clearly defined state.
As we keep on building upon this method we might need to take into account more biomarkers
(including DNA, RNA, protein and metabolomic profile, etc.) associated with various kinds of
tumor before we have a viable treatment method. In the next two sections, we extend the scope of
this method to the domain of heterogeneous cancerous tissue which implicitly deals with bridging
faults and pathways with feedback.
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3. UNDERSTANDING CANCER TISSUE HETEROGENEITY USING BAYESIAN
HIERARCHICAL MODELS ALONG WITH EVOLUTIONARY GAME THEORY
3.1 Introduction
Cancer is generally a result of the introduction of various mutations within cells, which in
turn make the cells neoplastic and give them a selective proliferative advantage over their normal
neighbors [35]. To target cancer, we need a methodology to understand and represent the various
biochemical regulatory processes that occur within the cell. Information collected by biologists
over a long period of time has resulted in a wealth of available information about cellular bio-
chemical processes and their regulation. Thus, it is apt to use such knowledge, also known as
signaling pathways, while devising methods for the treatment of diseases such as cancer which
result from a breakdown of cellular regulatory processes. A method making use of prior pathway
knowledge to build a Boolean signaling model was presented in [16]. In this work the proteins
within a cell which are in an active state are represented by the Boolean state 1 while the proteins
which are in an inactive state are represented by the Boolean state 0. The direct interaction of the
various proteins in a cell has been represented by the use of logic gates. In a normal cell, the state
of the upstream protein dictates the state of the downstream proteins but that may no longer hold in
the case of a mutated cell. In many of these cases, the mutations can thus be rightly represented by
stuck-at-faults which means a protein is either perpetually active (stuck-at-one) or rendered com-
pletely inactive (stuck-at zero) regardless of what states the upstream protein may be in. In certain
cases, the mutations can also be represented by a bridging fault.
Tumors can be such that the nature of mutations in all the cells are similar. In such cases the
tumors are said to be homogeneous in nature. The work in [16] showed how to design therapy
for tumors where there is a single stuck-at mutation along the signaling pathway of the cancerous
cells. This work has been further extended in the work [3], as shown in section 2, where tumors
of a homogeneous nature but with multiple mutations, are handled by making use of the concept
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of monotonicity in Boolean networks. More often than not, however, tumors tend to have hetero-
geneous subpopulations i.e. different cells of the tumor tend to have a different set of mutations
[35, 22] which can make the problem of treating cancer more complex. The work done in [26]
takes a step in this direction and shows how to deal with such heterogeneous tumors assuming
that the nature of mutations in the various subpopulations are known beforehand. The accuracy of
compositional breakup prediction achieved in that work requires improvement and accomplishing
that will be a major focus of this section. Another factor which also needs to be taken into ac-
count for cancer therapy design is the interaction between the various subpopulations of the tumor
[36]. In this section, we will also try to combine the knowledge of proportional breakup of various
subpopulations and the interactive relationship between them to identify the subpopulation which
needs to be targeted so as to improve and customize cancer treatment for patients.
In the subsections 3.2, 3.3 we design two Bayesian hierarchical models which built upon the
work in [26] and are shown to improve the accuracy. We then move on to make use of evolu-
tionary game theory to exploit the dynamics at play amongst the various sub-populations and use
it along with the knowledge of proportional breakup of the subpopulations to identify the target
sub-population. Finally, we present a brief discussion of the results and a concluding subsection.
3.2 Bayesian hierarchical model I
In this subsection we will present a modified Bayesian hierarchical model [26] which will
allow us to estimate the proportional breakup of the various tumor subpopulations. In case of a
heterogeneous tissue there are different subpopulations each with a different set of mutations in the
cell. Thus, it can be clearly seen that due to difference in the nature of mutations in these different
subpopulations they will respond differently to the application of various drug stimuli. This dif-
ference in response is what will help us in identifying the proportional breakup of the various sub
populations in the tumor tissue. One thing we should note here is that the observed values could
be gene/protein expression or it could be something else which allows us to differentiate between
the various subpopulations.
The authors in [16] presented a Boolean model of the growth factor signaling pathway which
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has been reproduced here in Figure 3.1. This model represents the signaling within a normal cell
which is free of mutations. In case of mutated cells there will be stuck-at-faults at various locations.
To represent a heterogeneous population, we will have to use an ensemble of Boolean networks
where each network describes a different subpopulation. Next, we describe the model below.
3.2.1 Intuition for the model
Let us consider a hypothetical scenario where there are three subpopulations in a tumor. Let us
suppose that the cells in the first subpopulation have a mutated PTEN gene. Thus, in this case the
PTEN protein is downregulated as it is supposed to be a tumor suppressor gene [37]. This can also
be seen from Figure 3.1 where an inactive PTEN will lead to an upregulated output. In the second
subpopulation let us assume that the Ras gene [22] has been mutated and in the third subpopulation,
suppose the mTOR gene [38] has been mutated. Our goal is to identify the proportional breakup
of these subpopulations in the tumor.
Suppose we observe the expression levels of BCL2 protein in the signaling pathway model
shown in Figure 3.1(a) in the two scenarios when the first drug combination (U0126, LY294002)
is applied and the second drug combination (U0126, LY294002, Temsirolimus) is applied. The
usual method to compute normalized expression values is by using the delta-delta method [29]
with GAPDH being used as the housekeeping (reference) gene for the first normalization step
and the second normalization step involving a control experiment. In our case for the control
experiment we simply observe the expression levels of BCL2 without the application of any of the
drugs.
A useful way to model the normalized expression values [26] is to represent them as ratios
between two normally distributed variables with a standard deviation value which is proportional
to the mean. The constant of proportionality between the standard deviation and the mean is called
the coefficient of variation. This coefficient of variation is assumed to be the same for all such
normally distributed variables. A justification for making this assumption is provided in [39].
In order to get an intuitive feel for how the model can be used, we initially assume that the
coefficient of variation is 0. Then we assume that when a protein is downregulated in a subpopula-
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Figure 3.1: (a) The Boolean model of the growth factor signaling pathway along with the proteins
which are involved in the signaling (b) shows the protein kinase inhibitors and their target proteins
along the signaling pathway. (Reproduced from [3])
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Table 3.1: The upregulated states are represented by 1 and the down regulated states are represented
by a 0.
No U0126 U0126 +
Drugs + LY294002 +
Applied LY294002 Temsirolimus
Subpopulation 1 1 1 1
Subpopulation 2 1 0 0
Subpopulation 3 1 1 0
tion the contribution of that subpopulation to the expression level of that protein is θ and when the
protein is upregulated the contribution of that subpopulation to the expression level of that protein
is 1. Let us represent the impact of subpopulation i on the expression level of protein p normalized
with respect to the housekeeping gene by αp,i. Similarly, when the protein is downregulated its
impact is αp,i × θ. The table 3.1 shows whether the protein BCL2 is upregulated or downregulated
for the three defined subpopulations in the presence of the drug combinations being considered.
This can also be predicted on the basis of the model presented in figure 3.1. This response profile
of the observable (i.e the protein expression) will now be referred to as the expression profile. For
example, when drugs U0126 and LY294002 are applied the expression profile is [1 0 1] across the
three subpopulations.
Let us represent the final normalized expression value for the protein p under the impact of drug
combination j on the heterogeneous tumor sample as γp,j . Now we can obtain an expression for
the observed normalized expression values in terms of α’s. The value will be the summation of the
impact of the various subpopulations under the effect of the drug combination and then normalized
by values obtained by the control experiment.
γBCL2,1 =
αBCL2,1 + αBCL2,3 + θ × αBCL2,2
αBCL2,1 + αBCL2,2 + αBCL2,3
(3.1)
where U0126+LY294002 is the drug combination 1.
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γBCL2,2 =
αBCL2,1 + θ(αBCL2,2 + αBCL2,3)
αBCL2,1 + αBCL2,2 + αBCL2,3
(3.2)
where U0126+LY294002+Temsirolimus is the drug combination 2.
As we are interested in the proportional breakup of the various subpopulations we can safely
assume that:
αBCL2,1 + αBCL2,2 + αBCL2,3 = 1 (3.3)
Thus, we can obtain the equations 3.4 and 3.5 as below;
αBCL2,1 + θ × αBCL2,2 + αBCL2,3 = γBCL2,1 (3.4)
αBCL2,1 + θ(αBCL2,2 + αBCL2,3) = γBCL2,1 (3.5)
Hence, from equations 3.3, 3.4 and 3.5 we can easily compute the proportional breakups of
the various subpopulations in the tumor as we have three independent equations in three variables.
This is the intuition which forms the basis of the model presented in [26] assuming that θ =
0, that is ignoring θ. However, we will update this by taking into account the fact that when a
protein in downregulated it does not have zero impact as assumed. In fact, we can see from the
experimental data in [3] and [26] that even in the downregulated state, the expression values for a
protein need not be zero. Hence let us assume that the average value of a downregulated observable
(protein/gene/etc.) is non-zero and is stored in θ. The benefit of assuming a non-zero θ is that we
can also account for the variation in the expression values when the observable is downregulated,
which is impossible for a zero valued θ due to the use of coefficient of variation to obtain the
standard deviation. This non-zero value for θ is obtained from prior knowledge.
Another important thing to keep in mind is that the contribution of the various subpopulations
on the various observables need not be the same as the relative ratio of the subpopulations [26]
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Figure 3.2: Hierarchical Model I showing all the conditional dependencies of the latent variables
and observed variables. The observed variables are shown in green, the latent variables are shown
in purple and the fixed variables which are either used to fine tune the model or represent some
prior knowledge in the model are shown in red.
themselves. Thus, we need to have varying relative ratio parameters for each observable while
making use of the information obtained on the basis of observation of these observables. Keeping
this in mind we move on to describing the model.
3.2.2 Model Description
The hierarchical model is presented in Figure 3.2. Here we can see the conditional dependen-
cies amongst the variables. First, we define the variables in the model. In the model let us assume
that there are l observables and N subpopulations. The observable could refer to gene/protein or
it could be something else too as we shall see later in this section. Let K denote the concentration
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parameter of the Dirichlet prior on the distribution of subpopulations within the tumor and also the
distribution of the contribution of the subpopulations to the various observables. The relative ratio
parameter αi = [αi,1, αi,2, · · · , αi,N ]T represents the gene expression ratio for each gene i across all
the subpopulations. θ, which was first defined in the previous subsubsection 3.2.1, represents the
mean value associated with the absence of activity across all the observables. di,j is an N dimen-
sional expression profile representing the presence or the absence of activity for the jth observation
of the ith observable across all the subpopulations. For example di,j = [1 0 1]T means that for the
jth observation the observable i is active for the first and third subpopulations but inactive for the
second subpopulation. D is the collection of all such di,j’s. ri,j is the jth normalized observation
for the ith observable. The normalization to obtain ri,j is done against the value obtained from
the control experiment where the observable is active in all the subpopulations. c is the coefficient
of variation associated with the observations made for the various observables as defined in the
previous subsubsection 3.2.1. λ is the parameter which controls the exponential prior distribution
of K. ν0, c0 are the parameters of the inverse-gamma distribution which forms the prior on the
hidden variable c.
Now we present the mathematical relationship between the child variables and their parent
variables in this hierarchical model. Equations 3.6 - 3.8 show the distributions from which the
random variables are derived. In equation 3.6, the Gamma distribution has a shape parameter
ν0
2




. In equation 3.7, λ is the rate parameter of the exponential












Ki ∼ Exp(λ) (3.7)
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αi ∼ Dir(K) (3.8)
Next we define a variable bi,j in equation 3.9. bi,j is a modified expression profile obtained
from di,j and represents the fact that an inactive observable need not have zero expression level.
bi,j = di,j + θ × (1 − di,j) (3.9)
where 1 represents a vector of ones.
Equations 3.10 - 3.12 tells us how the variable ri,j is sampled given the parent variables shown
in the hierarchical model presented in Figure 3.2. Note that N (x, y) represents a normal distribu-
tion with mean x and standard deviation y.
Oi,j ∼ N (bTi,jαi, cbTi,jαi) (3.10)
Ti,j ∼ N (uTαi, cuTαi) (3.11)





Note that in equation 3.11 the vector of ones is used instead of bi,j in order to represent the
control case where the observable is active for all the subpopulations. As αi is derived from a
Dirichlet distribution all its elements add up to a one. Thus in equation 3.11 it is interesting
to note that the variable ti,j is obtained from a normal distribution centered around the mean 1
with a standard deviation c. Now we need to establish a direct relationship between ri,j and its
parent variables c, θ, αi and di,j . Using a method similar to that shown in [26] we try to find the
probability density function over the space (Ri,j, Ti,j) given the density function over the space
(Oi,j, Ti,j). Note that the random variables Oi,j and Ti,j are independent of one another so the joint
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distribution is simply a product of the marginal distributions of Oi,j and Ti,j . In order to obtain the






∣∣∣∣∣∣∣ = |Ti,j| ≃ Ti,j (3.13)
The reason for approximating the modulus of Ti,j is that normally in such scenarios the distri-
bution has a very thin tail in the negative region due to the values of the coefficient of variation
c being small [39]. This gives us equation 3.14 and integrating over Ti,j we obtain the density
function for Ri,j in equation 3.15.
PRi,j ,Ti,j(ri,j, ti,j) = POi,j(oi,j)× PTi,j(ti,j)× J (3.14)














where mi,j = bTi,jαi.
Note that exp(k) refers to ek, where as Exp(k) refers to an exponential distribution with rate
parameter k. Once we have defined the relationship of variables with their parent variables the
primary goal is now to estimate the posterior distribution of K which in turn would give us an
idea of the distribution of the relative ratio of the subpopulations within the tumor. In Bayesian
modeling one way to achieve this is to make use of Markov chain Monte Carlo (mcmc) techiniques.
In order to implement the mcmc methods we first need to compute the full conditionals of the
unknown hidden variables. The derivation of full conditionals is similar to those shown in [26].













































where α−i represents all the αj’s such that j ̸= i and mi,j are as defined earlier in equation
3.15. Now before we proceed further we need to assign values for fixed variables like D, θ, v0,
c0 and λ. D is derived from the prior knowledge about an observable being active or inactive in a
subpopulation for each of the observations. For example, in the case where protein expression is
the observable we can predict whether the protein is active or inactive using the signaling pathway
knowledge as shown in Figure 3.1. θ is obtained from prior knowledge as mentioned in the previous
subsubsection 3.2.1. v0, c0 and λ are chosen such that the prior distribution for K and c are flat
compared to the posterior distribution. The reason we choose such parameter values is so as to
represent our ignorance about the distribution of the hidden parameters K and c.
3.2.3 Model Implementation
We will be making use of the Metropolis-Hastings algorithm [40, 41, 42] to sample from the
posterior distribution of the hidden variables K, c and α. The reason for using Metropolis-Hastings
is that the full conditionals obtained in equations 3.16 - 3.18 are not standard distributions from
which we can easily sample data points as required for Gibbs sampling [43, 44] are not easily
invertible as required by slice sampling [45] and we need to make use of proposal distributions
which might not be symmetric as required by the Metropolis algorithm [46]. The use of full
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conditionals in the Metropolis-Hastings algorithm or any other mcmc algorithm for that matter
allows us to sample from the true posterior distribution of each of the hidden unknowns in the
hierarchical model.
Although c can be generated from its full conditional as it involves the use of inverse-gamma
distribution but K and α have full conditionals which are not standard distributions. Thus, in
Metropolis-Hastings we make use of the proposal distributions to generate new samples. In the
case of K we use a symmetric proposal distribution. We sample an element K∗i from the uniform
distribution over the closed interval [Ki−UK , Ki+UK ] where Ki is the ith element of K and UK is
a tuning parameter which needs to be chosen carefully so as to allow for good mixing and ensuring
that the value of K is also updated often. We set the value of UK as 10. If K∗i < 0 then update the
value of K∗i to −K∗i . Using the method described in [42] we calculate the acceptance ratio ARK
as shown in equation 3.19. Then we update K to K∗ with a probability of min(1, ARK).
ARK =
P (K∗|α, c, r;D, θ)
P (K|α, c, r;D, θ)
(3.19)
In order to sample from the full conditional of α, we follow a similar procedure as mentioned
for K. Here we choose a new value of α∗i from a Dirichlet distribution (i.e. the proposal distribu-
tion) with the concentration parameter Uα × αi. We chose a value of 100 for the tuning parameter
Uα during the course of our simulation. Then we compute the acceptance ratio ARαi as shown in
equation 3.20 where Dir(x|Cp) refers to the probability of x given a Dirichlet distribution with
concentration parameters Cp. We update αi to α∗i with a probability of min(1, ARαi).
ARK =
P (α∗i |K, c, α−i, r;D, θ)×Dir(αi|Uα × α∗i )
P (αi|K, c, α−i, r;D, θ)×Dir(α∗i |Uα × αi)
(3.20)
In the prior distributions of c we use a value of 1 for v0 and a value of 0.1 for c0 in equation 3.6.
We set λ as 0.01 for the prior distribution of K as defined in equation 3.7 so as to provide a large
range for K but also to make sure that the value of K does not blow up during the mcmc process.
The mcmc method requires us to sample iteratively from the full conditionals and letting the pro-
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cess run till it attains stationarity. We use a burn-in period of 100000 and drop the initial 100000
samples so that the Markov chain attains stationarity and the samples are more representative of
the posterior distribution of the latent variables. We ran the Markov chain for 10000000 iterations
after the burn-in period and used a thinning factor of 1000 i.e. picked 1 sample out of each 1000
samples in order to reduce the correlation between consecutive samples and make sure that the data
were well mixed. Thus, we obtained a total of 10000 samples. Finally, in order to plot the marginal
posterior distribution of the relative ratio parameter representing the proportion of various subpop-
ulations we use the samples of K generated during the mcmc process and use it as concentration
parameters of the Dirichlet distribution as mentioned earlier in the model to sample α. Then, we
used the inbuilt function ‘ksdensity’ in MATLAB which uses a Gaussian kernel and logarithmic
transformation for boundary correction [47, 48] in order to plot the posterior probability density
function (pdf) of the hidden variables (primarily for the relative ratio parameters). Finally, we use
the mode of the pdf for the relative ratio parameter to give the final estimate of the proportion of
the various subpopulations.
3.2.4 Application on qPCR data
In this dataset, normal adult fibroblast cell lines are used and normalized gene expression ratios
are obtained using qPCR. The details of the experimental process undertaken to obtain this data are
given in [3, 26]. We look at the reporter genes that have the response elements for the transcription
factors SP1 and SRF-ELK (please see to Figure 3.1). EGR1 is a reporter for SRF-ELK [49] and
cMYC, JUN, IRF3 are reporters for the transcription factor SP1 [31, 32, 50]. Some more genes
which report on SP1 are BIRC5, Decorin, VEGFA [51, 52, 53, 54]. The normalization to obtain the
final gene expression values is done with respect to the control case where no drugs were applied
[3, 26].
In order to obtain the value of θ we take a simple average over all the expression data presented
in [3] for which a gene is inactive. This value of θ came out to be 0.37337. The observation dataset
used was the complete qPCR gene expression dataset presented in [55] and also has been presented
here in Table 3.2 for the convenience of the reader. The table shows the expression profile di,j and
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the observation data ri,j obtained from the experiments. As the data obtained is based on a single
type of cell line which corresponds to a normal subpopulation without mutations we assume two
fictitious mutated subpopulations. The second subpopulation is assumed to have a stuck-at-one
fault at ERK1/2 and the third subpopulation is assumed to have a stuck-at-one fault at the SRF-
ELK1 and SRF-ELK4 locations. Now given the mutation location, type of mutation and drug
applied we can predict the output for the reporter genes on the basis of Figure 3.1 and obtain the
expression profile di,j for the subpopulations. The drug combinations applied are only LY294002
for group 1 and LY294002 with U0126 for group 2 which would result in the di,js shown in table
3.2.
The dataset was fed to the model and as mentioned earlier we expect that subpopulation 1 (i.e.
the normal cells) should have a relative ratio equal to 1 and the other two subpopulations (i.e.
the mutated cells) should have a relative ratio equal to 0 each. Our calculations give us results
which are very close to the actual values. We also ran the method presented in [26] using the same
parameter values as described in our model while ignoring the variable θ. The results for our model
and the one in [26] (i.e. without θ) are given in table 3.3. Figure 3.3 shows the posterior distribution
of the elements of the relative ratio parameter as derived from the data using our model. We can
see that the model presented in this section clearly outperforms the model presented in [26] and is
very close to the actual relative ratio parameter values.
3.2.5 Application on Fluorescence data
In this dataset, cells from three different human cancer cell lines were used. The cell lines are
HCT116 (colon carcinoma), A2058 (metastatic melanoma) and SW480 (colorectal adenocarci-
noma). The cell lines are marked with specific fluorophores so that they emit specific wavelengths
of light under excitation which helps in identifying the cells [56]. The HCT116 cell lines were
marked with red wavelength emitting fluorophores and A2058 was marked with green wavelength
emitting fluorophores. Two different mixtures using these three cell lines in varying proportions
were considered and no drugs were applied to these mixtures. The general procedures for preparing
the samples are described in [56].
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Table 3.2: This table shows the expression profile (i.e. the expected state of the observable (gene)
for the first, second and third subpopulations) and the observation data (i.e. the normalized gene
expression values). (Reprinted from [55] c⃝ 2016, IEEE.)
Observables Group 1 Group 2
↓ Expression Observation Expression Observation
profile (di,j) (ri,j) profile (di,j) (ri,j)














BIRC5 1 1 1 0.5799 0 1 0 0.3842































The red/green emission level for each of the individual cells in each of the samples was mea-
sured but we do not make use of that information in our model. The average green wavelength
emission level and red wavelength emission level were the observable attributes for this experi-
ment. Each mixture had a total of 18 replicates for which emission level was measured and thus
we had a total of 18 average emission values for each of the green and red wavelengths. The ac-
tivity of each single cell line was separately measured too but we only make use of the average
emission level for green/red wavelengths when they are supposed to be active and inactive (for
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Table 3.3: Comparison of the estimated relative ratio values using our model and model presented
in [26] with the actual relative ratios using qPCR data.
Relative Ratio Subpopulation Subpopulation Subpopulation
Parameters ↓ 1 2 3







Figure 3.3: The marginal posterior distribution for each of the relative ratio parameters are shown
here. This shows that the normal subpopulation consists of almost the entirety of the population.
example in the case of the A2058 cell line, green wavelength fluorescence is supposed to be ac-
tive and red wavelength spectrum is supposed to be inactive) separately over all cell lines and all
replicates.
The average activity level for an active green/red emission wavelength is used to normalize
all our observations for the mixtures for green/red emission values respectively. The value of θ
is calculated as follows. First, the green signals associated with the cell lines where the green is
supposed to be inactive are averaged out. Thereafter, the same procedure is repeated for the cell
lines where the green is active. Then dividing the inactive average by the active average, we obtain
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Table 3.4: This table shows the expression profile (i.e. the expected state of the observable
(green/red emission) for the first, second and third subpopulations) and the observation data (i.e.
the normalized emission values).
Mixtures
Mixture # 1 Mixture # 2→
Observables
Green Red Green Red→
Replicate










2 0.44 0.40 0.28 0.19
3 0.43 0.29 0.12 0.55
4 0.48 0.38 0.25 0.31
5 0.31 0.50 0.17 0.36
6 0.44 0.41 0.12 0.40
7 0.52 0.35 0.19 0.28
8 0.52 0.29 0.10 0.33
9 0.53 0.22 0.18 0.26
10 0.41 0.37 0.19 0.47
11 0.46 0.31 0.11 0.68
12 0.43 0.45 0.37 0.20
13 0.38 0.31 0.21 0.33
14 0.43 0.47 0.21 0.35
15 0.46 0.40 0.28 0.42
16 0.27 0.32 0.31 0.66
17 0.42 0.27 0.13 0.42
18 0.40 0.32 0.21 0.42
the θgreen. In a similar way, we compute θred and θ is obtained as the arithmetic mean of θgreen
and θred. The value of θ came out to be 0.00289, which is very close to zero. Thus, the individual
cell data are only used to contribute to the prior knowledge contained in θ and as the normalizing
factor for the average green/red emission levels for the two mixtures so that the value of r can
be determined. Table 3.4 shows the expression profile (di,j) and the observation data (ri,j) for
mixtures 1 and 2.
This dataset was fed to our model and the model described in [26] (without using θ) and the
results are compared in table 3.5 for both the mixtures. We can see that for the fluorescent dataset
our method performs slightly better than the model in [26].
One of the reasons for the minor difference in the performance is that the value of θ is close to
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Figure 3.4: The marginal posterior distribution for each of the relative ratio parameters are shown
here for mixture 1 of the fluorescent dataset.
Figure 3.5: The marginal posterior distribution for each of the relative ratio parameters are shown
here for mixture 2 of the fluorescent dataset.
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Table 3.5: Comparison of the estimated relative ratio values using our model and model presented























zero and hence it is as good as setting a θ at zero i.e. a model without θ. We discuss further about
this in subsection 3.5. Figures 3.4 and 3.5 show the posterior distribution of the elements of the
relative ratio parameter as derived from the fluorescent data using our model.
We can see in the figures how the peaks also closely correspond to the actual proportion of the
various subpopulations in the dataset. In the next subsection we will see how we can update the
value of θ using the mcmc method when we do not have any prior knowledge of θ.
3.3 Bayesian hierarchical model II
In the previous subsection we saw how we can make use of the prior knowledge of average
inactivity levels over all the observables to further improve detection accuracy of the Bayesian
hierarchical model. In this subsection, we try to answer the question about what could be done if
we do not have the prior knowledge about θ. This scenario can also be resolved using the mcmc
method subject to certain conditions. Now let us see what we might need to be able to achieve
similar levels of accuracy as model I when θ is unknown.
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3.3.1 Brief intuition for the Model
Let us revisit at the example described using equations 3.1-3.5 and table 3.1. Equations 3.3-3.5
are the final equations which were used to solve for the αs. However, the value of θ was known.
If θ were unknown then we would need one more equation to solve for 4 unknowns. Hence, this
means that for three subpopulations to compute the three relative ratio parameters along with the
value of θ we need to have data pertaining to at least four unique expression profiles so that we
have four equations to solve for the four unknowns. Thus, if we have n different subpopulations
then we would need n + 1 independent equations to solve for the relative ratio parameters and θ
simultaneously which means we would need the data to have at least n+1 independent expression
profiles.
3.3.2 Model Description and Implementation
The model is shown in Figure 3.6. In this case the variable θ is a hidden variable controlled by
the shape parameters s and t of a Beta distribution. This relationship is described in equation 3.21.
θ ∼ Beta(s, t) (3.21)
The conditional dependence of the rest of the variables on their parent variables remain the
same as described in equations 3.6-3.15. Now we need to compute the full conditionals for all the
hidden variables. Luckily, for the hidden variables c, K and α the equation for the full conditionals
are the same as described in equations 3.16-3.18. Thus, we need only compute the full conditional
for θ. This is derived and described in equations 3.22 and 3.23 respectively.
P (θ|K, c, α, r;D) ∝ P (θ)× P (r|α, c, θ;D) (3.22)
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Figure 3.6: Hierarchical Model II showing all the conditional dependencies of the latent variables
and observed variables.












× θs × (1− θ)t
(3.23)
We used the value [s, t] = [1, 9] for the prior parameters. This represents the belief that θ is
closer to zero. As the full conditional of θ is a non-standard distribution we need to make use
of proposal distribution as required by the Metropolis-Hastings algorithm for implementing the
model. Given a current value of θ we choose a new value of θ∗ from the Beta distribution with the
shape parameters Uθ × θ and Uθ × (1 − θ). We used a value of 100 for the tuning parameter Uθ.
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Table 3.6: This table gives the updated expression profiles to be used instead of the ones shown in
table 3.2 for testing the model II.
Expression profile Updated
in table 3.2 expression profile
1 1 1 1 1
0 1 1 0 1
0 1 0 0 0
We update θ to θ∗ with a probability of min(1, ARθ) where the acceptance ratio ARθ is defined in
equation 3.24.
ARθ =
P (θ∗|K, c, α, r;D)
P (θ|K, c, α, r;D)
× Beta(θ|Uθ × θ
∗, Uθ × (1− θ∗))
Beta(θ∗|Uθ × θ, Uθ × (1− θ))
(3.24)
The rest of the fixed parameters apart from D (which varies on basis of data) and mcmc process
variables are kept the same as in Model I.
3.3.3 Application to qPCR data
We apply the model II described in this subsection to qPCR data. We make use of the same
observation data as described in table 3.2. However, as mentioned earlier we need to have data
pertaining to enough expression profiles so as to be able to estimate the relative ratio parameters
and the value of θ. For testing this model, we assume only two subpopulations, one being the
normal subpopulation and the other being a mutated subpopulation with mutations in the locations
SRF-ELK1 and SRF-ELK4 in the signaling pathway. Hence, the expression profiles in table 3.2
are updated as shown in table 3.6.
The mcmc process was run and the results are shown in table 3.7 and the posterior distribution
of the marginals of the relative ratio parameters are shown in figure 3.7. We see that even when θ
is unknown the estimated values are equal to the actual relative ratio parameters up to four decimal
places.
Now we move on to the next subsection where we look at how to combine the estimated
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Table 3.7: Compares the estimated relative ratio values (up to 4 decimal places) obtained using
Model II and the actual relative ratio values.
Relative Ratio Subpopulation Subpopulation
Parameters ↓ (Normal) (Mutated)
Actual 1 0
Estimated 1.0000 0.0000
Figure 3.7: Plot of the marginals of the posterior distribution of the relative ratio parameters ob-
tained from applying Model II to the qPCR data.
relative ratio parameters for the subpopulations and the information on interactions between sub-
populations to identify the target subpopulation.
3.4 Identifying the Target subpopulation
Estimating the proportion of the various subpopulations is one step in the process of finding the
subpopulation which needs to be targeted. Simply targeting the largest subpopulation [26] regard-
less of other considerations may not be the best solution [36] for the patient. The next step is to
actually identify the target subpopulation given the relative proportion of the subpopulations within
the tumor. In order to correctly identify a target subpopulation, we need to clearly define what we
want to achieve by targeting the subpopulation. Hence, our primary goal is to treat or manage the
metastatic cells. The reason is that the metastatic cells are the primary cause of mortality [57] in
64
Table 3.8: Payoff Matrix when two players are pitted against each other in a game (any situation






a (pa,c, qc,a) (pa,d, qd,a)
b (pb,c, qc,b) (pb,d, qd,b)
cancer patients. If there are no metastatic cells in the population then our aim would be to maxi-
mize reduction in the growth rate of the tumor. In order to find out the target subpopulation we will
make use of the existing knowledge regarding the interactions between various cell types using the
framework of evolutionary game theory (EGT). There is a body of literature [36, 58, 59, 60] on
how to exploit the knowledge of interactions of different subpopulations while designing therapies
for cancer. Here, we describe briefly the basics of evolutionary game theory and then look into a
few interesting scenarios on how to make use of evolutionary game theory.
3.4.1 Evolutionary Game Theory
A very good introduction to evolutionary game theory (EGT) is provided in [61, 62]. In game
theory, the idea is to look at the payoff when a particular strategy is paired off with another strategy.
By looking at these payoffs we can predict what strategies might fare better in a particular situation.
So normally the payoffs between all pairs of strategies amongst two players can we written in a
matrix form. Hence, in each entry of the matrix we have the payoff for a strategy when paired off
with another strategy and vice versa. Therefore, each entry has two values as shown in the example
in table 3.8. The p’s are payoffs player I receives when paired off with player II strategies and
similarly, q’s are the payoffs for strategies of player II against strategies of player I. For example,
player I will receive a payoff pa,c when player I is using a strategy ‘a’ and player II is using a
strategy ‘c’.
However, in the case of evolutionary game theory (EGT) we are looking at the interactions
within a population. Hence in a population, players refer to the population as a whole, strategies
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Table 3.9: Payoff table for the population types ‘1’, ‘2’ and ‘3’. Each row gives the fitness of a
particular individual type.
Population
1 2 3type →
↓
1 f1,1 f1,2 f1,3
2 f2,1 f2,2 f2,3
3 f3,1 f3,2 f3,3
correspond to different types of individuals (or behavioral phenotypes) [34] and the payoffs corre-
sponds to fitness (or reproductive success) [59] of the various types within the population. Thus,
we have the same strategies or population types along both the rows and columns as we are looking
for interactions between the various population types. Thus, we can write the fitness matrix a bit
differently as shown in table 3.9 where fx,y refers to the reproductive success or fitness of type ‘x’
when interacting with individual type ‘y’.
Thus, given the payoff matrix F (for example like the one shown in table 3.9 and the proportion
of the individual types within a population (vector P ) we can calculate the fitness of each popu-
lation type (T ) by simply using equation 3.25 below. For example, consider the three population
types ‘1’, ‘2’ and ‘3’ as shown in table 3.9. Suppose the relative ratio of these population types is
P = [p1, p2, p3]
T where p1, p2 and p3 are the proportion of type ‘1’, type ‘2’ and type ‘3’ respec-
tively. Then fitness of type ‘1’ is t1 = f1,1p1+ f1,2p2+ f1,3p3 and similarly we can calculate t2 and
t3 easily by using the vector form of the equation as shown in equation 3.25. The average fitness
‘A’ of the whole population can be easily derived by using equation 3.26.
T = FP (3.25)
A = P TT = P TFP (3.26)
This gives the replicator equation (RE) [61, 62] shown in equation 3.27 for population type
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Table 3.10: Payoff table for the population types ‘1’, ‘2’ and ‘3’. The fitness of each subpopulation
type is the same as the others regardless of the interacting cell types.
Population
1 2 3type →
↓
1 1 1 1
2 1 1 1
3 1 1 1
‘i’ which describes the evolution of the types within the population. This basically shows that
the difference between the fitness of type ‘i’ and the average fitness of the population controls the
growth rate of population type ‘i’. Note that although pi is not a continuous variable but for a large
enough population [60, 61] this is a good approximation.
dpi
dt
= pi(Ti − A) (3.27)
Note that as Σipi = 1 we are not looking at the total size of the population but rather just the
relative ratio of the various types within the population.
3.4.2 A Few Interesting Examples
Here, we will simply look at a few interesting examples involving different cell types in cancer
and show how they would be handled within this framework. This subsubsection simply serves to
show instances of how useful EGT can be when used in conjunction with our model to estimate
the relative ratio parameters. A general solution to the problem is beyond the scope of the current
work. We show four examples here.
3.4.2.1 Example 1
Consider the case when we have three subpopulations and none of them is metastatic. Their
payoff matrix is given in table 3.10. Suppose their relative ratio is given as [0.33, 0.4, 0.27] and
we have drugs to target each cell type.
Using equation 3.25 the fitness for the individual types comes out to be [1, 1, 1]T and using
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Table 3.11: Payoff table for the population types ‘1’, ‘2’ and ‘3’. The fitness of each type is fixed
regardless of its interaction.
Population
1 2 3type →
↓
1 3 3 3
2 2 2 2
3 4 4 4
equation 3.26 the average fitness comes out to 1. Now using the RE in equation 3.27 we get










]T = [0, 0, 0]T (3.28)
From this we can see that all the subpopulation types have a zero-growth rate of cellular fre-
quency within the tumor. Hence in this case we end up targeting cell type ‘2’ which has the highest
relative ratio among all the cell types in the tumor.
3.4.2.2 Example 2
Consider the case when we have three subpopulations and none of them is metastatic. Their
payoff matrix is given in table 3.11. Suppose their relative ratio is given as [0.33, 0.4, 0.27] and
we have drugs to target each cell type.
Using equation 3.25 the fitness for the individual types comes out to be [3, 2, 4]T and using
equation 3.26 the average fitness comes out to 2.87. Now using the RE in equation 3.27 we get










]T = [0.0429, −0.348, 0.3051]T (3.29)
From this we can see that the cell type ‘3’ has the maximum growth rate of cellular frequency
within the tumor. Hence in this case we end up targeting cell type ‘3’ within the tumor even though
it has the lowest relative ratio among all cell types.
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Table 3.12: Payoff table for the population types ‘1’, ‘2’ and ‘3’. The three phenotypes in the game
are autonomous growth (AG), invasive (INV) and glycolytic (GLY). The base payoff is 1 and the
cost of moving to another location is c. The fitness cost of acidity is n, whereas k is the cost of
having a less efficient metabolism (glycolytic). (Reprinted from [36], by permission of the Royal
Society)
Population
1 2 3type →
↓
1 1/2 1 1/2-n
2 1-c 1-c/2 1-c
3 1/2+n-k 1-k 1/2-k
3.4.2.3 Example 3
Consider the case where there are three cell types in the tumor. Type ‘1’ is metastatic in nature
and the other two types are non-metastatic. Also assume that we have appropriate drugs which
are able to target each of the subpopulation types. In this scenario we would not bother about the
relative ratio of the cell types and the payoff matrix for the cell types. We would simply target
cancer cell type ‘1’ as our primary goal here would be to reduce the spread of cancer within the
patients body. Hence in this example we do not bother about any other factor other than the fact
that we have available treatment for the only metastatic subpopulation within the tumor.
3.4.2.4 Example 4
In this example, the mix of cancer cell types and its payoff matrix has been reproduced from
[36]. Consider a scenario where subpopulation type ‘1’ is an autonomous growth, subpopulation
type ‘2’ is invasive in nature and type ‘3’ is glycolytic in nature. Suppose there are no drugs which
can directly target the subpopulation type ‘2’ but there are drugs which can directly kill off type ‘1’
and type ‘3’ subpopulation types. Here the relative ratio is given as [1/3, 1/3, 1/3] and the payoff
matrix is shown in table 3.12.
Here, our goal is to reduce the spread of the invasive (i.e. metastatic) cell type. We will try
and see which of the other subpopulations should be targeted in order to reduce the overall growth
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Figure 3.8: The sampling obtained for K in model I.
of the subpopulation type ‘2’. Suppose we target type ‘1’. Then in such a situation the type ‘2’
and type ‘3’ subpopulation no longer need to share resources with type ‘1’ subpopulation. Hence,
in order to calculate the RE we just need the payoffs due to interactions amongst type ‘2’ and
type ‘3’ subpopulations. Now both type ‘2’ and type ‘3’ are half of the active tumor population.
Hence fitness of subpopulation type ‘2’ is 1−3c/4 and fitness of subpopulation type ‘3’ is 3/4−k
using equation 3.25. So average fitness, using equation 3.26, is 7/8 − 3c/8 − k/2. Thus, using
the RE in equation 3.27, the frequency growth rates of type ‘2’ is 1/16 − 3c/16 + k/4 when we
target type ‘1’ subpopulation. Following the same steps, we calculate that when type ‘3’ is targeted
during treatment the frequency growth rates of type ‘2’ is 1/16− 3c/16. Thus, we can clearly see
that targeting type ‘3’ subpopulation or the glycolytic cell type, we would be better off in terms
of controlling the frequency growth rate of the type ‘2’ or the metastatic subpopulation. This is
similar in principle to what is mentioned in [36] and to what is shown in [59]. Hence, in this
example we target the type ‘3’ subpopulation.
3.5 Discussion
Before discussing the results, we need to be sure that the sampling done by the Metropolis-
Hastings method was done efficiently. Thus, we need to look at the autocorrelation of the concen-
tration parameters K and also a plot of the sampled values to see that the process achieved good
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Figure 3.9: The autocorrelation for K in model I.
Figure 3.10: The sampled values and autocorrelation for K in model II.
71
mixing. Figure 3.8 shows the sampled values of K and figure 3.9 shows the autocorrelation for the
K values in model I for the various datasets. For model II we can see both the sampling of K and
autocorrelation of K in figure 3.10.
We can see from the figures that the samples are well mixed and are very close to being ran-
domly sampled. We get similar results for the other estimated hidden variables during the mcmc
process in both the models. This means that the samples are truly representative of the posterior
distribution for the hidden variables.
In this section we have introduced two new Bayesian hierarchical models. These methods
do better in comparison to the method presented in [26] due to the fact that the inactive state
of an observable/attribute in real datasets need not be 0. Also, there can be a non-zero variance
associated with the inactive state of an observable. Since in our formulation, the standard deviation
is a multiple of the mean, a zero mean implies zero variance, which is a drawback of the method in
[26]. The introduction of a non-zero hidden variable θ allows us to model variance and a non-zero
mean associated with the inactive state of the observables. This helps to improve the estimation a
lot in cases where the mean inactive state is actually not close to zero. In case of the qPCR data
we can see that in an inactive state the average is close to 0.37 as obtained from [3] but in the
fluorescent dataset the average value for the inactive state is 0.003 which is very close to zero. This
is the reason that the model I outperforms the model in [26] (without θ) in case of the fluorescent
data by only a small amount but the difference in performance is much more pronounced for the
qPCR dataset. Another reason why our model outperforms the model in [26] for qPCR data is that
the data in that case is much noisier which is seen from the fact that the estimate of c comes out
close to 0.45. This contributes to a larger variance being associated with the inactivity levels of the
observables in the qPCR data.
In case of model II we also get an extremely good estimation accuracy. In fact, the estimated
values are equal to the actual relative ratio when calculated to four decimal places. This result is
even better than what we obtained in Model I with a fixed θ. This could be because of the fact that
model II had the freedom to automatically obtain the value of θ which allowed it to compute a better
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estimate for θ (the estimate came out to be 0.2676). The reason we have to use two subpopulations
for the qPCR data has to do with the number of underlying equations we get from the expression
profiles and the number of unknowns we need to estimate, as explained in the intuition for model
II. As we were estimating a new variable in model II (i.e. θ) we had to have one less unknown
element in α so as to allow for sufficient independent equations for the unknowns.
Finally, once the process of estimation is done we need to make use of EGT so as to intelligently
choose a target subpopulation. The existing literature on the use of EGT for cancer allows us to do
just that. We can clearly see by looking at example 1 and example 2, how the nature of interaction
between subpopulations leads us to choose different targets each time, even though the relative
ratio of the subpopulations is the same. In any scenario where we have a payoff matrix similar
to example 1 we would always choose the subpopulation with the highest relative ratio as the
target, assuming that none of them is metastatic. If we have a single metastatic subpopulation
which can be treated directly then we always target the metastatic subpopulation regardless of the
relative ratio values or the payoff table as demonstrated by example 3. If we cannot directly target
a metastatic subpopulation then using the principles of EGT we can target it indirectly as shown in
example 4. There can be a large number of different possible scenarios. A general solution using
EGT is beyond the scope of this work, but the idea here is to show how EGT could go along with
the method of relative ratio estimation of subpopulations in order to customize cancer treatment.
3.6 Conclusion
In this section we looked at the problem of estimating and finally identifying the target sub-
populations within a tumor when the nature of subpopulations is known. We applied our model
successfully to different types of datasets. One thing we should note here is that the exact same
model worked well for both qPCR and fluorescent dataset because of the fact that the conditional
dependencies proposed in the model hold true for both the datasets. For example, the assumption
that the observed values were derived by the ratio of two normally distributed variables was valid
for both the datasets, due to the way in which they were normalized. Even if the same conditional
dependencies do not hold for the different datasets captured using various methods, the relevant
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hierarchical model could easily be worked out by using the principles presented here.
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4. CANCER HETEROGENEITY: AN ARTIFICIAL NEURAL NETWORK APPROACH
4.1 Introduction
Cancer is an umbrella term used to refer to a whole array of diseases caused by mutations,
chromosomal rearrangements, etc. with the property that the affected cell divide and grow uncon-
trollably. The disruption of the normal functioning within a cell gives it a proliferative advantage
over its normal neighbors [35]. To successfully target cancer or manage the progression of cancer,
we need to thoroughly understand the underlying mechanisms in cell division, cell growth and cell
death. The interactions between various proteins involved in cellular processes can be modelled
in various ways such as Boolean modeling [16, 3] and differential equations [6, 7]. Making use of
such models it becomes possible to reasonably predict the behavior of the protein signaling under
different conditions (such as under the presence of mutation, under the influence of protein kinase
inhibitors, etc.). However, in the case of cancer we might not always have knowledge of the exact
nature of the mutations and how the protein signaling pathways are affected. Hence, the problem
takes a different form where we might have the observed data for the activity of some key proteins
and on the basis of that we try and identify the type of treatment we are supposed to give a patient.
In this section our focus is to customize treatment for each patient on basis of the observational
data we have at hand.
There is already some existing literature tackling the problem of treatment customization for
cancer. In [16] the authors propose a method to identify the best drug combinations under the
condition that a single protein has been mutated in the signaling pathway of the cells within the
tumor. In another work [3] this was extended to include the scenario where there might be multiple
mutations within the signaling pathway of the mutated cell. In both of these works, the tumor was
assumed to be homogeneous in nature i.e. the nature of the mutations in all the tumor cells was the
same. Another work [26] described a method applicable when the tumor is heterogeneous in nature
i.e. the nature of the mutations within the different tumor subpopulations is different. This work
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devised a method to identify the proportion of various subpopulations assuming that the nature of
the various subpopulations is known. This work was refined further in [4] (also shown in section 3)
by improving the accuracy of the method and making use of evolutionary game theory to identify
the target subpopulation in order to better customize treatment. However, these methods cannot be
extended to situations where the nature of the mutations in the subpopulations is not known a priori
and the tumor is heterogeneous in nature. For example, it will be extremely tedious to extend the
rules presented in [3] to heterogeneous tumors even if the required conditions are satisfied. Also,
the works in [16, 3] only deal with tumors where the mutation referred to as stuck-at-faults cause
a gene/protein to be constitutively active or to be rendered inactive. It does not apply to scenarios
where a mutation referred to as bridging faults in [16, 3] could introduce new signaling mechanisms
in the signaling pathways. We need to be able to address these mutations too. The range of the
possible mutations and the spectrum of the possible combinations of these mutated subpopulations
in a heterogeneous tumor make the problem of analyzing and estimating the proportion of various
subpopulations of tumor as described in [26, 4] extremely difficult, especially when the nature of
the subpopulations within the tumor is unknown.
Motivated by this, our primary goal is to develop a model to be able to identify the best possible
drug combination for a patient while minimizing the possible side effects. This model should be
able to address the various types of mutations which behave either as stuck-at-faults or as bridging
faults along the signaling pathway. Our model should also be able to deal with a heterogeneous
tumor regardless of the number of subpopulations or the interactions occurring between these
various subpopulations. To do so, we resort to creating two feedforward neural network models
trained using backpropagation to learn the hidden structure of the observed data. This model will
help us in identifying the best possible drug combination given the observation data collected from
the tumors.
In the next subsection we describe a method to generate synthetic data so as to capture the var-
ious uncertainties associated with the actual observed data. We also briefly discuss the real-world
data collected from actual cancer cell lines. Then we move on to describing the neural network
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models and present the results that were achieved using these models both on the synthetic data
and on the observed data. Then we present a discussion of our work and a concluding subsection.
4.2 Cancer Datasets
In this subsection we describe the process underlying the generation of the synthetic data which
has been used for the purpose of studying the usefulness of a neural-network based model in the
context of treatment customization for cancer patients. We also give a brief overview regarding the
real-world dataset collected from cancer tissues.
4.2.1 Synthetic Data Generation
Our objective is to make the synthetic data as realistic as possible. In the synthetic data gen-
erated for this work, the input consists of the activity level of genes transcribed by transcription
factors and reporter genes under the influence of different drug combinations and the output con-
sists of binary vectors indicating the presence or absence of drugs in the drug combination used for
treatment. Each data point corresponds to a single patient. Thus, the input is basically the expres-
sion level of a fixed set of proteins under different conditions and the output is the best possible
drug combination for the particular scenario. The goal of customized therapy is twofold. First, we
want to reduce the activity of the aggressive subpopulations within the tumor and second, we want
to reduce the side effects of the drug on the patient by using the minimal number of drugs. The
data points generated take into account the heterogeneous nature of cancer. Keeping this in mind
we describe the process of data generation in more detail.
As the tumors are mostly heterogeneous in nature one of the key characteristics we decide for
each of the data samples is the number of subpopulations that are present in the tumor. The total
number of subpopulations is obtained by adding one to a random number generated from a Poisson
distribution centered at 3. The reason for adding 1 to the randomly generated Poisson variable is
to eliminate the scenario where we have 0 cancerous subpopulations within the tumor. Thus, the
average number of tumor subpopulations we have over the complete dataset is 4.
Another variable which has to be decided upon, is the possible mutation locations in the tumor
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Figure 4.1: (a) The Boolean model of the growth factor signaling pathway (proposed in [16]) along
with the proteins which are involved in the signaling (b) shows the protein kinase inhibitors and
their target proteins along the signaling pathway. (Derived from [3])
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Figure 4.2: The evolution of cancer is shown here with branching occurring at 3 time steps and
thus a total of three mutated subpopulations after the final time step.
cells. On the basis of the existing knowledge, we have selected some of the key genes associated
with cancer such as IGFR [63], Ras [64, 65], IRS1 [66, 67], AKT [68], MEK1 [69] and mTOR
[70, 38, 71] as the possible mutation locations along the growth factor (GF) signaling pathway
(shown in Fig. 4.1). Thus, some of these genes would be mutated in the various subpopulations
within a tumor. Another thing to note here is that, as we have at least one mutation in each
subpopulation, the total number of different subpopulations possible is 26−1 = 63. Thus, the total
number of subpopulations cannot exceed 63. But, there is always a chance, however miniscule,
that we obtain a number greater than 63 in the previous step while deciding the total number of
subpopulations. In such a situation we simply discard the value and randomly pick an integer from
the set {1, 2, 3, , 63} with an equal probability.
Once we have settled on the number of subpopulations and the location of the mutations, the
next step is to decide on the subpopulations to be introduced in the tumor. In order to decide
on the subpopulations to be introduced, we make use of the branching model [72, 73] of cancer
evolution. Thus, as shown in the examples presented in figure 4.2, initially we have normal cells
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only represented by green colored cells. The first mutation is introduced at some time t = t1 during
the process of cell division. This new mutated subpopulation is represented by the blue colored
cell, which forms the entirety of the tumor as shown in figure 4.2. Next, at time t = t2 another
mutation is introduced to the already mutated cell to give rise to a new subpopulation (represented
by orange cells in both fig. 4.2(a) and 4.2(b)). Thus, in both these examples the blue cell has a
single mutation but the orange cell has two mutations. Finally, at time t = t3 one of the mutated
subpopulations within the tumor further gives rise to a third subpopulation. In fig. 4.2(a) the blue
subpopulation gives rise to the new subpopulation (shown in purple) with two mutations whereas
in fig. 4.2(b) the orange subpopulation gives rise to the third subpopulation (shown in red) with
three mutations. In fig. 4.2 there is a total of 3 time steps involved but if during the process of
generating a data sample we decide on n tumor subpopulations, then we would have n such time
steps.
We do not worry about the exact time when a new subpopulation is introduced because the total
number of subpopulations is fixed beforehand. However, we do need to decide which subpopula-
tion gives rise to the new subpopulation. We base this on the mutation rates of the subpopulations.
Thus, the higher the mutation rate, the greater is the chance for the subpopulation to mutate. There
is some evidence that a mutator phenotype is introduced at an early stage of the cancer [74, 75, 76]
which helps increase the mutation rates and thus leads to tumor heterogeneity. Keeping this in
mind we generate three kinds of datasets. In each of the datasets a different function controls the
relative mutation rate (relative to normal subpopulation) given the total number of mutations Nm
within a subpopulation. We describe the three functions in the equations 4.1-4.3.
f1(Nm) = 1 + 2.5× ln(Nm + 1) (4.1)
where ln represents the natural logarithm.
f2(Nm) = 1 + π ×
√
ln(Nm + 1) (4.2)
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Figure 4.3: The plot of the relative mutation rate vs the total number of mutations within a sub-
population.
where ln represents the natural logarithm.
f3(Nm) = 8× S(2×Nm)− 3 (4.3)
where S represents the sigmoid function.
As our data generation allows for a maximum of 6 mutations, (due to the 6 possible mutation
locations in the signaling pathway) we show how each of these functions behaves in the plot in fig.
4.3, for Nm ranging from 0 to 6. We can see that the function f1 provides for a more gradual rate
of increase in the mutation rate. However, the functions f2 and f3 take into account the mutator
phenotype which boosts the mutation rate as the first mutation is added and the first subpopulation
is created. The difference between f2 and f3 is that, the function f2 has a gradual rate of increase
in the mutation rate after the initial boost where as f3 quickly reaches a saturation point in the
mutation rate after the initial boost. Each of these functions is used to assign a weight (proportional
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to the mutation rate) to each of the existing subpopulations on the basis of the number of mutations
in them. These weights allow us to randomly select the subpopulation which will branch off into a
new subpopulation. Once the subpopulation is selected we allow for a new mutation to occur in the
subpopulation, with the specific mutation choice being equally likely from the remaining mutation
locations. If the new subpopulation has already been added to the population by the branching
off of another subpopulation, we discard it and again use the mutation rate functions fi to select
the subpopulation which will branch off and repeat the process all over again till we get a new
subpopulation.
During the implementation, instead of going over the process again and again we separately
allocate weights to all the subpopulations which could originate from the existing subpopulations.
This also helps to reduce the run time of the data generation algorithm. For example, consider
the scenario at the end of all the time steps in fig. 4.2(a). Let us assume that the subpopulation
represented by blue cells has a mutation in the (Ras) gene, the subpopulation represented by the
violet cells has mutations at (Ras, mTOR) gene locations where as the subpopulation represented
by orange cells has mutations at (Ras, AKT) gene locations. Now suppose that we had 4 time
steps. Then, both the violet and orange subpopulations have equal chances of mutating and both
these subpopulations could lead to the subpopulation with mutations at (Ras, mTOR, AKT) gene
locations. Thus, in our implementation the subpopulation (Ras, mTOR, AKT) has twice the weight
of being the new subpopulation as compared to the subpopulation (Ras, mTOR, IRS1) or the
subpopulation (Ras, AKT, IRS1) both of which can originate from only one existing subpopulation.
Note that the existing subpopulation (Ras) could again branch off to give rise to (Ras, mTOR)
which already exists at the 4th time step. In order to avoid this type of situation we force the
weights of the existing subpopulations to be 0. Thus, this method allows us to directly select the
next subpopulation from the existing subpopulations in a single try.
Once we have selected the subpopulations we decide on the proportions of the various sub-
populations by deciding upon the relative ratio parameters controlling the impact of the various
subpopulations on the tumor as a whole. The relative ratio parameters are obtained from a Dirich-
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Figure 4.4: A hierarchical model portraying the generation of observations from an underlying
tumor tissue (derived from the model presented in [4]).
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let distribution with concentration parameter of dimension equal to that of the number of tumor
subpopulations. The concentration parameter K is a set of randomly selected real values in the
range (10, 150). The reason we allow for random relative ratio parameters is because the growth
rates of each of the subpopulations is normally different and also the time steps at which branching
occurs has a wide range of variation. The reason we limit the range of concentration parameters
to (10, 150) is so that the Dirichlet distribution is neither too sharp which will reduce variability
amongst the relative ratios of different genes, nor do we want it to be too much spread out and thus
remove any similarity between the relative ratio values of different genes. The relative ratio of the
various subpopulations is what controls the final observed output which we generate for our work.
A hierarchical model [40, 41, 42] describing the generation of observed values was first described
in [26] and refined further in [4] to obtain much better accuracy.
Figure 4.4 shows the hierarchical model derived from the work presented in [26, 4]. We have
utilized this model to generate our data. In figure 4.4, we can see the concentration parameter K
[26, 4] described earlier. αi, the relative ratio parameters, are obtained from the Dirichlet distri-
bution with concentration parameter K. Thus, αi represents the relative impact [26, 4] of each
subpopulation on the overall expression of the gene i in the tumor. In our data generation model,
we obtain the observation for the output nodes shown in figure 4.1. That refers to one gene tran-
scribed by each of the transcription factors FOS-JUN, SP1, SRF-ELK respectively and the reporter
genes BCL2, CCND1. Hence, we have five output genes for which we are generating observation
data and thus we have 5 αi’s. D is a set consisting of the vector di,j [26, 4] which represents the
gene expression profile for the jth observation for the ith gene across the various subpopulations.
For example, in a tumor consisting of 3 subpopulations if a gene i is supposed to be active for
subpopulation 1, inactive for subpopulation 2 and active for subpopulation 3 for the jth observa-
tion then di,j = [1 0 1]. This gene expression profile di,j can be computed by using the growth
factor signaling diagram shown in figure 4.1. In our case we assume that the input proteins (EGF,
HBEGF, IGF, NRG1, PTEN) have the values given in the tuple (0 0 0 0 1) i.e. all the inputs are
inactive except for PTEN which is active.
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Even in an inactive state the expression of the gene need not be exactly 0. It can be defined
to have an average value of θ [4] which is another hidden variable of the hierarchical model.
Thus, we get a modified expression profile bi,j = [1 θ 1]. The average expression value [26, 4] for
gene i in the jth observation will be the dot product of αi and bi,j i.e. αibTi,j . However, there is
always a variance associated with such observations [39, 77] which can be modeled by the final
hidden parameter c in the hierarchical model. c is the coefficient of variance associated with the
observations and thus the actual jth observed value for the ith gene would be a sample oi,j drawn
from the Normal distribution with a mean αibTi,j and a standard deviation c × αibTi,j . We used
c = 0.17 [39] and θ = 0.2676 [4] on the basis of our prior work. To obtain the final observed
values ri,j we normalize oi,j against the expression value ti,j of the gene in the control experiment.
In the control experiment, all the genes across all the subpopulations are forced to be active. Thus,
ti,j can be obtained by sampling from the Normal distribution with a mean 1 and standard deviation
c. Hence, ri,j is the ratio of two Normally distributed random variables [26, 4, 39].
Each gene is observed 4 times under the effect of the 5 different drug combinations which are
{No drugs, U0126, U0126 + LY294002, Temsirolimus, Temsirolimus + U0126 + LY294002}.
The 3 drugs and their specific target locations are shown in figure 4.1. When a drug is applied to
the tissue sample it renders the target protein/gene location inactive. Thus, using this knowledge
along with the information of the mutation locations and the input values we can easily compute
the expression profile di,j for all the genes. As we are observing 5 genes under the effect of 5 drug
combinations 4 times each, we have a total of 5 × 5 × 4 = 100 observations for a tumor tissue
sample. Thus, we generate 20000 vectors of dimension 100 each to form the training dataset and
separately generate 2000 vectors to form the testing dataset. We carried out this procedure thrice
and each time used a separate function defining the relative mutation rate.
Note that each observation vector in each of the datasets represents a sample obtained from a
single patient. In the dataset we also defined a target set for each of the observations. The drug
combination is decided upon by first identifying the most aggressive subpopulation in the mix. The
subpopulation with the maximum number of mutations is marked as the most aggressive. How-
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ever, if there are ties for the maximum number of mutations within the population then we choose
the subpopulation with the largest concentration parameter from among the ones with the most
number of mutations. The reason for this approach is to reduce the growth rate of the tumor while
minimizing the possible side effects from using too many drugs. Thus, our goal is to target the
most aggressive subpopulation instead of targeting all the subpopulations at the same time. The
drug combination which gives the best possible output but makes use of the least number of drugs
is marked using a binary vector. As we have 3 drugs we use a binary vector of size 3 to indicate
the presence or absence of the different drugs. For example, suppose a tissue sample has two sub-
populations where one subpopulation has a mutation in the Ras gene and the other subpopulation
has mutations in the Ras and the IRS1 gene. In this case the second subpopulation with two mu-
tations is considered to be the most aggressive. In a normal cell with no mutation and the input as
given earlier we expect all the outputs to be inactive. Hence, our goal is to drive all the outputs to
inactivity. We can see from figure 4.1 that applying the drug combination U0126 + LY294002 +
Temsirolimus we can force all the outputs to 0 whereas any drug combination consisting of a single
drug cannot achieve the same outcome. However, the two drug combination U0126 + LY294002
can also achieve the same result. We prefer the two drug combination U0126 + LY294002 rather
than the three drug one in order to have reduced side effects. This drug combination corresponds
to the binary vector (1 1 0).
By following the procedure described above, we generated a total of 3 datasets. We name the
datasets SD1, SD2 and SD3 where ‘SD’ represents synthetic data. The datasets SD1, SD2 and
SD3 were generated by using the relative mutation rate functions f1, f2 and f3 (defined in eqs.
4.1-4.3) respectively.
4.2.2 Real World Data Collection
The real-world dataset uses samples from three different human cancer cell lines. The cell
lines were collected from patients with colon carcinoma (HCT116), metastatic melanoma (A2058)
and colorectal adenocarcinoma (SW480). The cell lines are marked with specific fluorophores
and thus they emit specific wavelengths of light under excitation which can be used in identifying
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the cells [56]. In this case the HCT116 cell lines were marked with the red wavelength emitting
fluorophores and the A2058 cells were marked with the green wavelength emitting fluorophores.
The general procedures for preparing the samples are described in [56].
The observed values were collected using a simple experimental set up. During the start of the
experiment all the samples consisted of a mixture of the three cell lines in one of two different
relative ratios. Each of the samples were observed either under the influence of exactly one drug
such as Lapatinib and Temsirolimus or without the application of any drugs over a period of 48
time steps. Hence, the factors differentiating the observed samples were the initial proportion
of the cell lines the sample started with, the time step in which the data were collected and the
application of a specific drug or the absence of any drug. There were a total of 18 replicates of
the samples observed under similar conditions (i.e. same starting proportion, same time step and
similar drug application). For each sample the average green/red emission intensity for all the cells
was observed and calculated. We combined the green/red emission values from all the 18 replicates
to form a single vector of dimension 36. As we have a total of three drug combinations (i.e. only
Lapatinib or only Temsirolimus or no drugs), a total of 48 time steps and two different starting
proportion of mixtures, we have a total of 48 × 3 × 2 = 288 data vectors. The proportion of the
cell lines vary due to the effect of the different drugs over a period of time which make them very
useful for testing the efficacy of our feedforward neural network model. We also randomize the
ordering of these vectors in order to remove any dependence that might exist between consecutive
data vectors. As the number of vectors is only 288 and the dimension of each vector is large we
reduce the dimension of each of the vectors in order to avoid problems related to overfitting of the
model. We achieve this by combining the green/red emission intensity from sets of three sample
replicates. As there is a total of 18 replicates observed under similar conditions, we get 6 sets of 3
replicates each. We then take the average of the green/red emission values collected from each of
the sets and use these values to get our modified vector of dimension 36/3 = 12.
We then create a target binary vector of dimension 3 for each of these 288 vectors. In order to
do this, we first compute the relative proportion of the three cell-lines (i.e. HCT116, A2058 and
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SW480) averaging over the 18 replicates. This is computed by looking at the average emission
level of green/red wavelength obtained from all the individual cell lines (i.e. HCT116, A2058
and SW480) under the application of similar drugs and during the same time steps. The average
green/red emission values for the individual cell lines and that of the mixtures are used to compute
the relative ratio of the cell lines by solving a simple set of simultaneous equations. For example,
assume that the proportion of three cell lines HCT116, A2058 and SW480 is p1 : p2 : p3. Also
suppose the average green/red emission levels for the individual cell lines HCT116, A2058 and
SW480 are (g1, r1), (g2, r2) and (g3, r3) respectively. Also suppose that the average green/red
emission level for all the replicates of the mixture is (g, r). Then we solve the three simultaneous
equations 4.4-4.6 in order to obtain the relative ratios p1 : p2 : p3 of the cell lines in the mixture.
p1 + p2 + p3 = 1 (4.4)
p1g1 + p2g2 + p3g3 = g (4.5)
p1r1 + p2r2 + p3r3 = r (4.6)
We assume that the cell line which has the largest proportion in the samples corresponding to
the vector will be targeted for treatment and we assume a set of three fictitious drugs D1, D2 and
D3 which target the cell lines HCT116, A2058 and SW480 respectively. Thus, if A2058 forms
the largest subpopulation within the samples then we should use D2 for treatment and hence the
target vector is (0 1 0). Similarly, if SW480 forms the largest subpopulation then the target vector
is (0 0 1). Hence, this gives us a total of 288 data vectors and their respective target vectors.
Finally, we randomly choose 240 data vectors to form our training set and the remaining 48
data vectors forms our testing set. We name this dataset FD (abbreviation for fluorescent dataset).
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4.3 Neural Network Model
We train two feedforward neural network models on the cancer observation data. The goal is
to be able to predict the best possible course of treatment from a set of drugs on the basis of the
observation data. The advantage of using a neural network model is that it can directly learn the
hidden rules and the structure inherent to the data, without any human intervention. Now, we look
into the details of both the models, which we have trained in this work to learn the underlying
association between the observation data and the best drug combination for treatment. Both the
models are minor variations of each other and provide an advantage on different aspects of the
drug prediction as will be elaborated upon later.
4.3.1 Model I Description
As mentioned earlier, we have used a feedforward neural network model. This model has been
implemented by using the neural network toolbox in Matlab. The training data is broken up into
three blocks with the initial 80% of the data being used for training, the next 10% of the data being
used as the first validation set and the final 10% of the data being used as the second validation set.
The dataset has been randomized beforehand so as to prevent the neural network from training on
the data in a specific region of the feature vector space rather than generalizing over the complete
vector space.
As a preprocessing step we perform feature scaling of the data so as to transform the features
to the range [−1, 1]. This generally helps in faster convergence [78] of the model to its minimum.
It is trained using the scaled conjugate gradient backpropagation [79]. The details of this back-
propagation method are explained in [79]. This method is generally good for large datasets and
the synthetically generated dataset described in the previous subsection falls in that category. It
also works well for relatively smaller datasets as we shall see when we apply our model to the
fluorescent data obtained from cancer cell cultures. Mean squared error mse, shown in equation
4.7 is used to evaluate and backpropagate the errors during the training process, where Ns is the
total number of samples in the dataset.
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ΣNsi=1(yi − ti)T (yi − ti) (4.7)
where yi is the output vector and ti is the target value vector.
In our neural network model, we have used three hidden layers of the same size. The neural
network model diagram is shown in figure 4.5. Each node in the hidden layer uses a tan sigmoid





The nodes in the output layer use a linear activation function. The reason for using a linear
activation function in the output layer was to improve the performance as using a sigmoid activation
function in the output layer caused the performance to drop. This is due to the fact that it is very
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difficult to update the weights by backpropagating errors over the sigmoid activation function once
the node reaches the saturation region. Thus, the back propagated error is very small and the
change in the weight becomes negligible in each epoch of training. However, we do still use tan
sigmoid activation in the hidden layer because we do need the nonlinear nature of such activation
functions for the model to successfully learn the associations between the input and the target
output values. As we already have three hidden layers with non-linear activation functions we use
a linear activation function for the final layer. We also use a bias in all the layers (shown in solid
colors in figure 4.5) so as to account for any bias associated with the data or the output of the
previous layer. This is especially useful in the output layer considering the fact that the output of
the tan sigmoid activation function lies in the range (−1, 1) whereas we expect the output to be
approximately in the range (0, 1) since our target vector has binary values.
In order to obtain the final parameters, we calculate the mse of the first validation set in each
epoch and stop the training of the model when the mse of the first validation set does not improve
for 25 consecutive epochs. Then we roll back the model by 25 epochs and set the model parameters
to the values the model had when the mse for the first validation set was at the lowest. An example
is shown in figure 4.6 where we trace the mse obtained during the training of the model on dataset
SD3. This helps us to prevent the model from overfitting on the training data.
Once the model has been trained we need to find the threshold in order to help us decide
whether a drug is to be administered or not. In other words, the threshold helps convert the real
valued output into binary values 0 or 1. Since this is a classification task and the datasets are
unbalanced in the sense that approximately 0.75 of the target values in each of the three simulated
datasets are 1’s and exactly 2/3rd of the fluorescent dataset target values are 0’s we need to make
sure that the classification is balanced with respect to both the classes i.e. 0 and 1. Hence, we
make use of the Matthews correlation coefficient MCC [80, 81], popularly used in bioinformatics
[81, 82] for classification tasks, while choosing the threshold. We vary the value of the threshold
from 0 to 1 in steps of 0.01 and choose the value which gives us the largest value for the MCC on
the second validation set. The formula used to compute the MCC is given in eq. 4.9.
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Figure 4.6: Mean squared error (mse) plot obtained during Model I training using the SD3 dataset
showing the minimum on the validation set at epoch 305.
MCC =
TP × TN − FP × FN√
(TP + FP )(TP + FN)(TN + FP )(TN + FN)
(4.9)
Note that TP refers to the number of the true positives, TN refers to the number of true neg-
atives, FP refers to the number of false positives and FN refers to the number of false negatives
during classification. Figure 4.7 shows the MCC plots and receiver operating characteristic (ROC)
curves for each of the output nodes which were obtained while training model I using dataset SD3.
The final selected threshold value for each of the output nodes is marked in red in the correspond-
ing position on the MCC curve and on the ROC curve. We chose separate threshold values for
each of the output nodes, while training Model I, on all the datasets in a similar manner (i.e. by
using the MCC values for assessment).
We also set a limit, on the total number of epochs for which the model can train, at 1000.
The minimum allowed performance gradient is set at 10−6 and thus when the value drops below
the threshold the training is stopped. These settings allow us to prevent the model from training
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Figure 4.7: MCC curves and ROC plots obtained by varying the threshold values for a trained
Model I using SD3 datset.
indefinitely.
4.3.2 Model II Description
This model is a variation on the model described in the previous subsection. The training
dataset is split up into two blocks. The first block consisting of 80% of the data samples is used
for training the model and the remaining 20% of the data is used for validation purposes. Similar
to model I we use the same preprocessing and perform feature scaling. We make use of the scaled
conjugate gradient backpropagation method [79] to train our model.
In order to implement the model II we make use of the architecture shown in figure 4.8. Similar
to model I there are 3 hidden layers which use the tan sigmoid activation function as described in
eq. 4.8 and consist of the same number of nodes. The output layer uses a softmax activation.







Figure 4.8: Architecture of the feedforward neural network-based model II.
such that o(3)i is the output of the i






such that yj is the output of the jth node in the output layer.
Note that in eq. 4.10, i = 0 refers to the bias node which implies that o(3)0 is equal to 1 and Nh
is the total number of nodes in the hidden layer. In eq. 4.11 K is the total number of nodes in the
output layer.
As we are using a softmax output we modify the target vectors so that the model would be
compatible with the target vector. In this section we are dealing with the issue of identifying the
correct drug combination. Therefore, the modified target binary vector will be 1 for exactly one
output node, corresponding to the correct drug combination, and 0 for the rest of the output nodes.
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Table 4.1: Modification of target binary vectors so as to be compatible with SoftMax activation at
the output layer.
Original target vector Modified target vector
0 0 0 1 0 0 0 0 0 0 0
1 0 0 0 1 0 0 0 0 0 0
0 1 0 0 0 1 0 0 0 0 0
1 1 0 0 0 0 1 0 0 0 0
0 0 1 0 0 0 0 1 0 0 0
1 0 1 0 0 0 0 0 1 0 0
0 1 1 0 0 0 0 0 0 1 0
1 1 1 0 0 0 0 0 0 0 1
Note that all the data samples have an associated target binary vector of dimension 3. These 3
binary values in the target vector correspond to the 3 drugs which are being considered in the
datasets, as explained earlier. Thus, the total number of different drug combinations possible is
23 = 8. Hence, in order to modify the target vectors, we simply map each of the 8 possible target
binary vectors to vectors of length 8 as shown in table 4.1.
In this model we make use of the cross-entropy error function CEE for the purpose of eval-
uation and backpropagation of error during the process of model training. It is defined as the dot
product of the logarithm of the model output vector and the target vector averaged over all the data
samples (eq. 4.12).




i )× ti (4.12)
such that yi, ti are the model output and target vectors respectively for the ith sample and Ns is the
total number of samples in the dataset.
Similar to model I, we also compute the CEE over the validation set in each epoch of training
and stop the training of the model when the CEE of the validation set does not improve for 25
consecutive epochs. Then we roll back the model by 25 epochs and assign the model parameters
that the model had when the CEE for the validation set was at the lowest, as the final model
parameters. We get a plot similar to figure 4.6 but with the performance being measured by cross-
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entropy error. Again, as in model I we set the limit on the total number of epochs for which the
model can train at 1000. The minimum allowed performance gradient is set at 10−6 and thus when
the value drops below the threshold the training is stopped. These settings allow the models to
achieve the best possible weight values in an acceptable amount of time.
4.3.3 Implementation and Results
We train both model I and model II on each of the four datasets (i.e. SD1, SD2, SD3 and FD)
and get a total of 4×2 = 8 models. In the simulated datasets, the training data had a total of 20000
samples each with a feature dimension of 100. For these 3 simulated datasets we fix the size of
the hidden layers at 25 nodes (excluding the bias node) for both model I and model II. Increasing
or decreasing the size of the hidden layer causes the performance to drop. Thus, this was found
to be the optimum value to use given the dataset of this size. In the case of the fluorescent dataset
FD we had a total of 240 samples of dimension 12 in the training dataset. We definitely could not
use a model of the same size as used for the simulated datasets. The reason is that the number of
independent model weights we would have to learn from the training data would far exceed the
total number of data samples. Thus, when training model I and model II, for the FD dataset, we
found that the optimum size of the hidden layers was 3 nodes (excluding the bias). Thus, we had a
total of 13× 3+ 4× 3+ 4× 3+ 4×Nout = 63+ 4Nout < 100 weights to train, where Nout is the
total number of output nodes which varies depending on whether we are using model I or model
II.
Once we trained model I and model II for all the datasets we tested the models using the
corresponding test dataset. The test dataset as described earlier had a total of 2000 samples for the
simulated dataset and the fluorescent dataset had a total of 48 samples for testing.
Now we look at the results we obtained by applying both the models to the four datasets (three
simulated and the fluorescent dataset). We use 3 evaluation metrics during the testing of the model.
First, the drug combination accuracy (DCA) for both the models is calculated. In this evaluation
criteria we compare the predicted drug combination with the target drug combination. Second, the
drug prediction accuracy (DPA) is evaluated for both the models. In this evaluation criteria we
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Table 4.2: Confusion matrix for the example test set.
Total Predicted drug
drug usage usage values
values = 6 0 1
Actual Drug 0 TN = 2 FP = 0
usage values 1 FN = 1 TP = 3
Table 4.3: Testing Results for the four datasets using two types of models.
Datasets Model I Model II
↓ DCA DPA MCC DCA DPA MCC
SD1 81.50% 91.47% 0.7749 83.40% 91.47% 0.7763
SD2 80.90% 91.80% 0.7833 82.65% 91.68% 0.7787
SD3 81.80% 91.90% 0.7864 82.50% 91.72% 0.7812
FD 85.42% 91.67% 0.8148 87.50% 91.67% 0.8125
compare the predicted usage of the drugs individually to the targets. Third, we compute the MCC
value across all the output nodes combined for all the testing samples. This helps us in making
sure that the model is not biased in terms of the detecting whether a drug is to be used or not,
for treatment. Suppose we consider the example where we have two predicted drug combinations
[1 1 0], [0 1 0] and two corresponding target drug combinations [1 1 0], [0 1 1]. In the first evaluation
metric we will get an accuracy of 50% as one predicted drug combination matches with the target
combination. In using the second evaluation metric the accuracy would come out to be 83.33%
as five out of the six drug usage predictions match with the target values. For the third evaluation
metric we need to calculate the TP , TN , FP and FN values. These can be calculated from the
confusion matrix shown in table 4.2. Using eq. 4.9 we obtain MCC = 0.7071.
We evaluated both the models on all the 4 datasets using these 3 evaluation metrics. The results
are presented in table 4.3.
All these models were trained using scaled conjugate gradient backpropagation as mentioned
earlier and all these models stopped training when the performance of the model did not improve
for the validation for 25 epochs. For all the datasets while training model I we also decided on the
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threshold values using the MCC plots similar to those shown in figure 4.7.
4.4 Discussion
We can see that both of these models provide comparable results in terms of prediction accuracy
DCA, DPA and also the MCC values. However, if we observe closely we would see that model II
outperforms model I in terms of DCA by 1 to 2% for all the 4 datasets. This is understandable in
light of the fact that in model II each output node represents a single drug combination whereas in
model I each output node corresponds to a single drug. During the training of the neural networks,
model II learns the associations between observation vector and the specific drug combinations
directly whereas model I learns the relationship between observation vector and the corresponding
drug usage values. Thus, model II outperforms model I when we compute DCA.
Due to the nature of the target vectors used to train model I we can see that the model I always
outperforms model II when we use the evaluation metric DPA albeit by a small amount. The reason
we do not see a large difference in performance when comparing DPA for both the models is that
there are two competing factors here. Although learning the specific relationship between observa-
tion vector and the drug usage values does provide model I an advantage in the evaluation of DPA
but when model II learns the association between observation vector and the drug combination
correctly it gets three drug usage values correctly and thus improves its DPA. Thus, model I cannot
outperform model II by a significant amount on DPA evaluation metric as in the case with the DCA
evaluation metric. Hence, we can see that the DPA values are the same for both the models in the
datasets SD1 and FD and the model I has a greater DPA value than model II for datasets SD2 and
SD3.
In the MCC evaluation metric, model I outperforms model II on an average by a small amount.
The reason for this is that, we specifically select the binary thresholds for model I on the basis
of MCC calculation. Thus, it does help model I to improve its MCC during the evaluation of
the model. However, it does not provide a major advantage in terms of MCC evaluation due to a
competing factor which plays a role. We explain the competing factor by the use of an example.
Consider that we have these 4 target vectors in the dataset [1 1 1], [0 1 1], [1 0 1], [1 0 0]. If we
98
consider each of the output nodes, 3 out of 4 times the output is 1 and only once it is 0. In such
a scenario it is quite easy for the model I to be biased towards the output 1 by the very nature of
the dataset. However, if we look at model II each of the target vectors gives rise to 4 different drug
combinations which are represented by a different output node. The architecture of model II also
forces exactly one output node to have a maximum value, with a very high degree of probability,
and this node is considered to have a value 1 and the remaining output nodes have a value 0. Thus,
the architecture of model II allows the target data to be better spread out across 8 classes in this
example. This reduces the chances for the model to develop bias towards certain types of output.
Another interesting thing to note here is that DPA values are all greater than 90% whereas DCA
values lie within the range 80 − 90%. This is easily understood as for a drug combination to be
correct all three output nodes have to be correct whereas for a single drug prediction to be correct
just one output node needs to be correct. For example, consider the target vector [1 0 1] and suppose
we get the predicted vector [1 0 0]. This adds 2 correct predictions to the DPA score whereas it does
not contribute to the DCA score. Thus, mathematically speaking DCA≤DPA always holds true
when we are testing a particular model on a given dataset.
Thus, we see that each of the models do hold some advantage over the other. Given the nature
of the models, we can see that model II would be extremely useful in scenarios where multiple
drugs work in tandem in order to treat the patient. In such cases model II would better select the
correct drug combination. In scenarios where drug combination itself is not important but rather
we need more accuracy regarding the usage of drugs, model I would be a better option to use.
4.5 Conclusion
In this section we generated a simulated dataset to closely resemble real-world data obtained
from the cancer cell lines on the basis of existing knowledge. Then we trained two neural network
based models on the simulated datasets and also a fluorescent dataset. We saw the advantages of
using each type of model over the other. This section shows how neural network models are able to
realize the hidden associations between the observations and the target outputs even though there
is a lot of variations associated with such biological data. Another important step which needs
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to be taken is collecting more real-world data so that models of the types considered here can be
exploited to their fullest potential.
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5. SUMMARY AND CONCLUSIONS
5.1 Summary
In this dissertation, we have considered various problems with the common goal to find a way
to customize the drug treatment for cancer patients. The approach used to solve each of these prob-
lems exploits the monotonic properties of certain Boolean networks, the conditional dependencies
of the hierarchical models, the principles of evolutionary game theory and the learning potential
of the neural network models. In order to customize the treatment, we try to get the best possible
output in terms of containing the spread and growth of the tumor while minimizing the side effects
of the treatment at the same time.
First, in section 2, we looked at the scenario when the tumor is homogeneous in nature and
made use of Boolean networks satisfying monotonic properties [3] to predict the best possible drug
combination for the patients. Here our prediction is based upon the observations obtained from the
tissue sample under the influence of a subset of the possible drug combinations. However, the
signaling pathway has to satisfy the monotonic properties and the mutations have to correspond to
stuck-at-faults for this method to be applicable. The strategy of using a small subset of possible
drug combinations to predict the best possible drug combination is inherent to all the methods
presented in this work.
Second, in section 3, we solved the case when the tumor is heterogeneous in nature and we
have prior knowledge regarding the behavior of the subpopulations within the tumor. We applied
a Bayesian hierarchical models along with evolutionary game theory [4] in order to predict the
target subpopulation and consequently provide a method for the customization of cancer treatment
in such a scenario. The Bayesian hierarchical model allows us to accurately estimate the relative
ratios of the various subpopulations. Then, evolutionary game theory allows us to identify the
subpopulation which should be targeted first so as to achieve the best possible results in terms of
controlling the growth and spread of the tumor. This particular approach can deal with mutations on
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signaling pathways which need not satisfy the monotonicity requirement as dictated by the method
presented in section 2. This can also deal with the mutations which correspond to a bridging fault
assuming that the nature of the new signaling is known apriori. However, in this case we do make
the assumption that the nature of the all the constituent subpopulations of the tumor are known to
us either via the knowledge of mutations along the pathway or via some phenotypic behavior of
the tumor cells.
Finally, in section 4, we considered the scenario where the tumor is heterogeneous in nature
where the number of the subpopulations and/or nature of the subpopulations is unknown. We made
use of neural network based modeling [82] to identify the best possible drug combination. This
method is much more powerful as, in this case, we need not have any prior knowledge of the
subpopulations within the tumor and we need not make any assumptions as to the nature of the
signaling pathway or the type of mutations present. However, this method does make use of data
from lots of cancer patients whereas the methods presented in sections 2 and 3 only makes use of
the observation data from the single patient for whom we are trying to predict the best possible
drug combination and signaling pathway knowledge.
5.2 Further Study
There are various aspects of the problem which needs to be considered in the future so as to
bring this work closer to the realm of clinical applications. In this work we have just used the total
number of drugs as an indicator for the toxicity of a drug combination. We can further improve
upon this by making use of a detailed analysis of the toxicity of various drug combinations at
different concentrations so as to better customize the treatment for patients. Another way to make
our methods more useful is to improve the run time of our presented methods while maintaining
the accuracy levels of our model. Some work has been done in this regard in [57].
An important aspect of this research, which will be taken up later, is finding innovative ways
for feature selection in order to obtain features which are more discriminative in terms of deciding
the output. The use of relevant features will help us in achieving better estimation of the best
possible drug combination. This can be directly applied to all the methods presented in sections 2,
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3 and 4. We should also combine various categories of features (e.g. body mass index, hormone
levels, etc.) along with protein/gene expression, emission values to get more informative features
and get a better predictive model.
We made use of EGT along with the hierarchical model to demonstrate how powerful a tool it
can be when used alongside Bayesian networks. However, in order to use EGT we need to be have
the payoff matrix for various cell lines. One possible direction of research for the future could be
to try and estimate this payoff matrix by making use of the time series data or perhaps combining
the estimation of the payoff matrix along with the other hidden variables in the hierarchical model
to get a more comprehensive solution to the problem. The improvement in accuracy which has
been obtained in this work, in identifying the relative impact of the various subpopulations, makes
Bayesian hierarchical models more significant in the context of customizing cancer treatment and
hence an approach worth pursuing for further research.
Another possible direction of future research would be to make use of the time-series data
and the response of the patients to the various drug combination therapies over a period of time.
Such a model would not only learn which drug combination works best but also make use of the
knowledge regarding the drug combinations to which the patients did not respond well, during
treatment, and further improve the prediction of the best possible drug combination. Another thing
which such a model would take into account is the time duration involved for a patient to respond
to the various types of treatment. This direction of future research would definitely bring us a step
closer to achieving the goal of treatment customization for cancer patients.
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